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ABSTRACT
Pretargeted radioimmunotherapy (PRIT) of cancer improves upon conventional
radioimmunotherapy (RIT) by decoupling the pharmacokinetics of the targeting agent
and the radioisotope. In order to improve upon PRIT, we have considered variables such
as treatment setting and methodology, the transport and clearance characteristics of
targeting agents, and the radionuclides used for therapy. PRIT has been modeled with the
aim of examining the theoretical potential of PRIT under optimal conditions to kill every
cell in malignant, avascular micrometastases. A mathematical model of PRIT was
developed that combined a two-compartment pharmacokinetic model, antibody binding
kinetics, diffusion and catabolism in tumor spheroids, and radiation dosimetry models for
alpha- and beta-emitting radionuclides. This model demonstrated that it is theoretically
possible to kill every cell in 100 tm radius micrometastases using 9Y- or 213Bi-based
PRIT with acceptable toxicity as described. The therapeutic window for dosing
radionuclide-carrying hapten was found to be strongly dependent on cell-specific
parameters such as antigen concentration, void fraction, and the radiosensitivity
parameter a, as well as on targeting agent molecular parameters such as the diffusivity
and antigen-binding association rate. Surprisingly, the therapeutic window was
insensitive to the radiosensitivity metric a/I, the targeting agent antigen-binding
dissociation rate, and all pharmacokinetic parameters. Overall, 213Bi-based PRIT
significantly outperformed 9Y-based PRIT in terms of the safe therapeutic time window
for radiometal dosing and the degree of cell overkill that could be achieved.
An attempt was made to isolate high-affinity scFv or linear peptide binders
against the loaded metal chelate Ga-DOTA-biotin. Unfortunately, several different
approaches led only to scFvs and linear peptides with at best micromolar affinity for Ga-
DOTA-biotin. It is possible that Ga-DOTA-biotin is a difficult target against which to
engineer high affinity binders due to the chelate's six-coordinate binding of the gallium
ion, which may result in rapid exchange of the carboxyl arms of the chelate in solution.
As an alternative approach to targeting agent design, an anti-CEA, anti-fluorescein
single-chain bispecific diabody was designed, produced in S. cerevisiae and
characterized. The full-length diabody (55 kDa) binds CEA expressed on the surface of
colorectal cancer-derived SW1222 cells with a KI of 4.3 ± 2.5 nM, and also binds
fluorescein while bound to CEA on the cell surface.
Lastly, in order to assist in protein engineering via directed evolution,
asymptotically optimal probability estimation was combined with numerical
bootstrapping and non-linear curve fitting to make accurate predictions of the actual
underlying diversities of populations based on small samples of data.
To my parents, my first and best teachers.
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Chapter 1: Introduction and Background
Pretargeted radioimmunotherapy (PRIT) of cancer improves upon conventional
radioimmunotherapy (RIT) by decoupling the pharmacokinetics of the targeting agent
and the radioisotope. In order to optimize PRIT, we must consider variables such as
treatment setting and methodology, the transport and clearance characteristics of the
targeting agents, and the radionuclides used for therapy. Protein and peptide engineering
via directed evolution can be used to isolate improved reagents for PRIT. Asymptotically
optimal probability estimation can be adapted in order for protein engineers to better
estimate the underlying diversity of populations enriched for improved clones.
1.1 Origins and development of radioimmunotherapy
The idea of using antibodies to deliver radiation to cancer cells was proposed
immediately following the development of monoclonal antibody technology [1]. The
simplest form of radioimmunotherapy (RIT) is the direct conjugation of a radioisotope to
an antibody that binds specifically to cancer cells. Antibodies have in vivo biological
half-lives of days to weeks; radiolabeled antibodies in a patient's circulation result in
high doses of radiation to healthy tissues. A high dose to healthy tissues limits the
amount of antibody that can be administered, which in turn limits the success of the
therapy. Only extremely radiosensitive cancers can be effectively treated using this
conventional form of RIT [2].
1.2 Pretargeted radioimmunotherapy
Pretargeted radioimmunotherapy (PRIT) was proposed as an alternative to
conventional RIT in which the pharmacokinetics of the antibody and the radioactivity are
decoupled. In all PRIT treatments, a bispecific protein (hereafter refered to as the
targeting agent or bispecific) with specificities to both a cancer cell-surface antigen and
the radioisotope-carrying small molecule (hereafter referred to as the hapten) is
administered to the patient. The bispecific circulates throughout the patient's body,
where it will bind to accessible cancer cells. After remaining bispecific has cleared from
the patient's body, the hapten is administered. Because the hapten is typically a small
molecule, it will rapidly perfuse throughout the body and then clear quickly, binding only
to the hapten-specific part of the bispecific that is prelocalized to cancer cells. The
subsequent radioactive decay leads to cancer cell cytotoxicity and death, while the
patient's healthy tissues are spared. In three-step variants of PRIT, a clearance step in
added in which the targeting agent in the blood is removed from the body by the
administration of another molecule. This additional step does not, however, change the
fundamental idea behind the treatment - it simply speeds the clearance of the targeting
agent from the body.
The concept behind pretargeting has been in existence for more than two decades
[3, 4], yet to date has failed to realized its full potential. While it has had encouraging
successes in mouse xenograft models [5-7], PRIT has had marginal therapeutic success in
clinical trials [8, 9]. Next, we examine the different design decisions that need to be
considered in order to improve upon current methods and molecules employed in PRIT.
1.2.1 Treatment setting
Antibody-based cancer therapies, including PRIT, have been developed primarily
to target vascularized, heterogeneous solid tumors, as treating these tumors is an urgent
clinical need. However, there are many obstacles and disadvantages to using antibodies
for the treatment of solid tumors. First, there is the significant problem of delivering the
antibody to the tumor. Poor transport in tumors can place severe pharmacokinetic
restrictions on anti-tumor antibodies, and their large molecular mass exacerbates these
effects [10]. Second, the heterogeneous nature of these tumors makes them very difficult
to competely neutralize with a "magic bullet" therapy such as PRIT, as there are often
significant regions of non-antigen-presenting cells. Finally, the cells in the hypoxic and
necrotic regions of these tumors are often highly radioresistent. Notable exceptions -
such as Zevalin and Bexxar - have been successful only in the treatment of
pharmacokinetically accessible, radiosensitive cancers [2]. These issues also pFesent
significant barrier to successful PRIT of solid tumors that may be minimized or reduced
in mouse models, but will remain problematic in treating human patients. For these
reasons, rather than targeting solid tumors, we believe that PRIT is better suited for use as
an adjuvent therapy targeting avascular micrometastases, and have investigated the use of
PRIT in that setting in this work. For the purposes of this work, we define
micrometastases to be cancer cell clusters which have not initiated angiogenesis, and are
typically 100-300 [tm in radius.
1.2.2 Targeting agent selection
An extremely wide variety of antibody-based targeting molecules have been
proposed for or used in pretargeting studies, including: IgG-streptavidin [5], IgG-biotin
[11], bispecific mAbs, other bispecific antibody-based molecules, and antibody-DNA
fusions [12]. The streptavidin-biotin interaction was originally utilized in PRIT because
very high affinity interactions between proteins and small molecules were otherwise hard
to come by. There are two main problems, however, with using streptavidin and biotin to
link the targeting agent and the hapten. First and most important is the problem of
streptavidin's large size (53 kDa). When fused to an IgG, the resulting fusion protein is
quite large and faces significant transport limitations; streptavidin also makes a poor
hapten as it will not clear very rapidly from the circulation. The second limitation of
using the streptavidin-biotin linkage in PRIT is the problem of endogenous biotin, which
can compete with the biotin present on either the targeting agent or hapten. Although this
problem is fairly manageable in humans, endogenous levels of biotin are much higher in
mice, making murine to human comparisons of PRIT protocols more difficult. While
innovative solutions have been found to the endogenous biotin problem [13, 14], the
large size of streptavidin alone is reason enough to seek other molecules out as targeting
agents. The great advances in protein engineering that have been made during the
development of streptavidin-biotin-based PRIT now allow for the engineering of
extremely high affinity interactions in antibody-based molecules significantly smaller
than streptavidin.
1.2.3 Radionuclide selection
While the scope of this project did not include working with hot radiolabeled
hapten, it was necessary to select potential radionuclides of therapeutic interest so that
appropriate hapten molecules could be selected and designed. The choice of which
radionuclide to use for PRIT (or, more generally, for any type of radioimmunotherapy)
hinges on the following variables: particle type (alpha or beta), linear energy density
(LED) of radiation, radioactive half-life, and mean path length of the radiated particles.
Alpha particles tend to have shorter path-lengths (50-70 pm) than the electrons emitted
by beta-emitting radionuclides commonly used in radiotherapy, which may make them
better suited for targeting cell spheroids sized 100-300 pm, as the bulk of the energy
released by localized radionuclides will be deposited in the targeted cells, rather than in
the healthy tissues surrounding the spheroids [15]. Due to their much higher linear energy
density, alpha particles are also far more radiotoxic than beta particles, with only a few
alpha particle passes through a cell nucleus required to kill a cell under certain
circumstances [16]. However, alpha-emitting radionuclides are limited by a variety of
factors, including generally short half-lives (213Bi has a half-life of just 45 minutes), the
problem of radioactive daughter nuclide release from the site of localization [17], and to
date very low achievable specific activities in radiometal haptens, as compared to beta-
emitting radionuclides [18].
Most radionuclides used in RIT and PRIT today have relatively long path lengths
(for example, 1311 and 'Y have mean path lengths of 0.5-0.9mm and 5mm in tissue [19,
20]). This is to be expected, as they are used primarly in the treatment of solid tumors,
where their long path lengths can hit neighboring cells to which radioisotope has not been
localized. These long path lengths, however, are not ideal for treating micrometastases.
The ideal sizes of tumors for treatment with 90Y and 131I have been calculated to be 2 cm
and 3 mm, respectively [21, 22]; micrometastases are at least a full order of magnitude
smaller. As a result, beta-emitters with shorter path-lengths (such as 67Ga, with a mean
path length of 100 pm [23]) may be better suited for PRIT [24].
1.3 Protein engineering
When PRIT was first proposed as a method for treating cancer, the protein
engineering field was still in its infancy. Since that time, protein engineering has
developed to the point at which it is straightforward to develop extremely high affinity
antibodies against most antigens. Methodological advances in protein engineering such
as the introduction of directed evolution have been coupled with technological
innovations, such as the development of flow cytometry and fluorescent activated cell
sorting (FACS), to allow researchers to engineer higher-affinity, smaller, more specific
and more stable proteins than ever before.
1.3.1 Protein engineering via directed evolution
Perhaps the most powerful idea introduced to the field of protein engineering in
its history has been engineering via directed evolution [25]. In this method, a large
library of protein molecules is created using molecular biology techniques. This library
is then screened in a high-throughput manner that allows the selection of desirable clones
within the library. These clones are then subjected to rounds of mutation to create new
libraries, and the process is repeated until clones with the desired properties - i.e.
enzymatic activity, binding affinity, fluorescence or stability - have been isolated. In all
of the commonly-used variants of protein engineering via directed evolution, the
genotype and phenotype of the protein are physically linked, so that the retrieval of an
improved protein clone also yields its sequence information. The three primary
technological platforms for protein engineering via directed evolution are phage display
[26], yeast surface display [27] and ribosome/RNA display [28].
Phage display is the oldest and at present most commonly used platform for the
directed evolution of proteins. In phage display, one or more copies of the protein of
interest is expressed as a fusion on the surface of filamentous phage. A large library of
clones can then be panned by incubating the phage on immobilized antigen and washing
away non-binding phage. The main advantages of phage display are its ease of use, low
cost and the ability to screen extremely large libraries in single pannings. There are
several drawbacks, however: first, many proteins of interest are not properly folded when
expressed as fusion proteins on phage. Second, fusing the protein to the surface of the
phage changes its function significantly, and so clones of interest must be subcloned and
secreted solubly in order to be accurately evaluated. Finally, the screening process is not
quantitative, in that it can be difficult to tune the panning conditions in order to obtain
clones with specific properties.
In yeast surface display, proteins of interest are displayed on the surface of the
yeast Sacchromyces cervisiae by fusion to the Agal and Aga2 mating proteins. Because
proteins are processed by the yeast's eukaryotic secretory pathway, many proteins that
cannot be displayed on the surface of phage can be functionally expressed on the surface
of yeast. Screening clones displayed on the surface of yeast is typically done via
fluorescent activated cell sorting (FACS), rather than by panning. Large libraries of yeast
displaying many different protein mutants are created and fluorescently labeled under
conditions such that desirable mutants have a brighter fluorescent signal than the rest of
the library. Because the selection process is controlled by a computer and based on the
fluorescence of individual cells, yeast surface display selections can be performed in a
high quantitative manner [29]. The only drawback of yeast surface display is that library
sizes are limited by the throughput of cell sorters, which at present can sort
approximately 10" cells per hour, making libraries larger than 109 impractical to screen
via FACS. However, larger yeast libraries can also be sorted using magnetic activated
cell sorting (MACS), which is physically analogous to phage panning [30]. Recently,
Feldhaus and colleagues constructed a human non-immune library of single-chain
variable fragments (scFvs) displayed on the surface of yeast [31] from which antibodies
of therapeutic interest have been isolated [32].
In ribosome display and closely-related mRNA display, the RNA coding for a
protein and the expressed protein itself are physically linked. This RNA-protein fusion
can then be panned directly against target molecules. The advantages of ribosome
display include the lack of a transformation step, which drastically increases the sizes of
libraries that can be constructed, and very rapid selection cycling. Disadvantages include
the problems with protein folding and expression that might be expected in the absence of
an organism's secretory pathway [33].
1.3.2 Peptide engineering
The display and screening methods discussed above can also be used to isolate
short peptides against targets of interest. Constrained peptide libraries are commonly
displayed on the surface of phage and screened against various small molecule [34] and
protein targets [35-37], but linear peptide libraries have also been displayed on the
surface of yeast and screened for binding to patterned material surfaces [38, 39].
Mutagenesis is often performed in between selections rounds when doing protein
engineering, but this is not the case for peptide engineering. Because of the short length
of peptides, peptide libraries are typically only screened once, and then resynthesized
with conserved residues held constant. Libraries can be easily synthesized using
commercially available oligonucleotides.
1.4 Asymptotically optimal probability estimation
In the late stages of successful protein engineering efforts, a population of
improved clones is isolated. These improved clones have often been generated and
isolated at great expense, time and effort of the individual or company doing the protein
engineering. It is in the interest of that individual to examine each and every improved
clone, since some clones will be better than others in terms of the characteristic being
selected for, while others will be desirable in other unintended ways (for example, they
might happen to be easily secreted, or very stable, etc). The question then arises: how
many unique clones are present in the enriched population? This is a surprisingly
difficult question to answer because the investigator typically has at his or her disposal
only an incomplete sample set of the total number of clones in the population. For
example, one might sequence 50 improved single clones, and discover that 30 are unique.
How many total unique clones are present in the population, and how many clones must
be sequenced in order to come across every clone? These questions are of both scientific
and practical importance - rare clones could possess novel biochemical or biophysical
properties, but the benefit of isolating them must be balanced against the cost and time
spent sequencing and characterizing individual proteins.
Orlitsky and colleages have developed an improved algorithm for asymptotically
optimal probability estimation that can be used to directly address the common problem
in protein engineering discussed above [40].
1.5 Thesis Overview
This document presents the work accomplished towards the goal of optimizing
PRIT treatment methods and therapeutic reagents. In Chapter 2, a comprehensive model
of PRIT is developed in which it is shown that PRIT can be successfully used to kill
every cell in avascular micrometastases embedded in normal tissue. In Chapter 3, efforts
directed at isolating gallium-DOTA(1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic
acid)-biotin-binding scFvs and linear and constrained peptides for use as part of a
bispecific targeting agent are described. Chapter 4 presents the application of
asymptotically optimal probability estimation to the problem of diversity estimation in
protein or peptide engineering. Finally, in Chapter 5, an alternative targeting agent is
developed in which the targeting agent binds to both carcinoembryonic antigen (CEA)
and fluorescein; radioactive payloads of almost any type can then be conjugated to
fluorescein to create the hapten reagent. This targeting agent was constructed at the DNA
level, secreted from S. cerevisiae, and characterized in solution and on the surface of
CEA-expressing mammalian cells.
1.6 Works Cited
1. Kohler, G. and C. Milstein, Continuous cultures of fused cells secreting antibody
ofpredefined specificity. Nature, 1975. 256(5517): p. 495-7.
2. Dillman, R.O., Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-
CD20 monoclonal antibodies. Clin Exp Med, 2006. 6(1): p. 1-12.
3. Goodwin, D., et al., Use of specific antibody for rapid clearance of circulating
blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med,
1984. 9(5): p. 209-15.
4. Goodwin, D.A., et al., Monoclonal antibody hapten radiopharmaceutical
delivery. Nucl Med Commun, 1986. 7(8): p. 569-80.
5. Zhang, M., et al., Pretargeting radioimmunotherapy of a murine model of adult T-
cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood, 2002.
100(1): p. 208-16.
6. Pagel, J.M., et al., Comparison of anti-CD20 and anti-CD45 antibodies for
conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood,
2003. 101(6): p. 2340-8.
7. Subbiah, K., et al., Comparison of immunoscintigraphy, efficacy, and toxicity of
conventional and pretargeted radioimmunotherapy in CD20-expressing human
lymphoma xenografts. J Nucl Med, 2003. 44(3): p. 437-45.
8. Grana, C., et al., Pretargeted adjuvant radioimmunotherapy with yttrium-90-
biotin in malignant glioma patients: a pilot study. Br J Cancer, 2002. 86(2): p.
207-12.
9. Knox, S.J., et al., Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-
LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer
Res, 2000. 6(2): p. 406-14.
10. Jain, R.K., Transport of molecules, particles, and cells in solid tumors. Annu Rev
Biomed Eng, 1999. 1: p. 241-63.
11. Sung, C. and W.W. van Osdol, Pharmacokinetic comparison of direct antibody
targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl
Med, 1995. 36(5): p. 867-76.
12. Chang, C.H., et al., Molecular advances in pretargeting radioimunotherapy with
bispecific antibodies. Mol Cancer Ther, 2002. 1(7): p. 553-63.
13. Hamblett, K.J., et al., A streptavidin-biotin binding system that minimizes
blocking by endogenous biotin. Bioconjug Chem, 2002. 13(3): p. 588-98.
14. Hamblett, K.J., et al., Role of biotin-binding affinity in streptavidin-based
pretargeted radioimmunotherapy of lymphoma. Bioconjug Chem, 2005. 16(1): p.
131-8.
15. Behr, T.M., et al., High-linear energy transfer (LET) alpha versus low-LET beta
emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-
limiting toxicity of 213Bi- versus 90Y-labeled COI 7-A Fab' fragments in a
human colonic cancer model. Cancer Res, 1999. 59(11): p. 2635-43.
16. Charlton, D.E., Radiation effects in spheroids of cells exposed to alpha emitters.
Int J Radiat Biol, 2000. 76(11): p. 1555-64.
17. McDevitt, M.R., et al., Tumor therapy with targeted atomic nanogenerators.
Science, 2001. 294(5546): p. 1537-40.
18. McDevitt, M.R., et al., An alpha-particle emitting antibody ([213Bi]J591) for
radioimmunotherapy ofprostate cancer. Cancer Res, 2000. 60(21): p. 6095-100.
19. Behr, T.M., et al., Cure of metastatic human colonic cancer in mice with
radiolabeled monoclonal antibody fragments. Clin Cancer Res, 2000. 6(12): p.
4900-7.
20. Witzig, T.E., et al., Randomized controlled trial of yttrium-90-labeled
ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for
patients with relapsed or refractory low-grade, follicular, or transformed B-cell
non-Hodgkin's lymphoma. J Clin Oncol, 2002. 20(10): p. 2453-63.
21. Perkins, A., In vivo molecular targeted radiotherapy. Biomed imaging interv J,
2005. 1(2): p. e9.
22. Wheldon, T.E., et al., Modelling the enhancement offractionated radiotherapy by
gene transfer to sensitize tumour cells to radiation. Radiother Oncol, 1998. 48(1):
p. 5-13.
23. Howell, R.W., Radiation spectra for Auger-electron emitting radionuclides:
report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys, 1992.
19(6): p. 1371-83.
24. Michel, R.B., M.W. Brechbiel, and M.J. Mattes, A comparison of 4 radionuclides
conjugated to antibodies for single-cell kill. J Nucl Med, 2003. 44(4): p. 632-40.
25. Wittrup, K.D., Protein engineering by cell-surface display. Curr Opin Biotechnol,
2001. 12(4): p. 395-9.
26. Paschke, M., Phage display systems and their applications. Appl Microbiol
Biotechnol, 2006. 70(1): p. 2-11.
27. Boder, E.T. and K.D. Wittrup, Yeast surface display for screening combinatorial
polypeptide libraries. Nat Biotechnol, 1997. 15(6): p. 553-7.
28. Rothe, A., R.J. Hosse, and B.E. Power, Ribosome display for improved
biotherapeutic molecules. Expert Opin Biol Ther, 2006. 6(2): p. 177-87.
29. Boder, E.T. and K.D. Wittrup, Optimal screening of surface-displayed
polypeptide libraries. Biotechnol Prog, 1998. 14(1): p. 55-62.
30. Siegel, R.W., et al., High efficiency recovery and epitope-specific sorting of an
scFv yeast display library. J Immunol Methods, 2004. 286(1-2): p. 141-53.
31. Feldhaus, M.J., et al., Flow-cytometric isolation of human antibodies from a
nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol,
2003. 21(2): p. 163-70.
32. Colby, D.W., et al., Development of a human light chain variable domain (V(L))
intracellular antibody specific for the amino terminus of huntingtin via yeast
surface display. J Mol Biol, 2004. 342(3): p. 901-12.
33. Lipovsek, D. and A. Pluckthun, In-vitro protein evolution by ribosome display
and mRNA display. J Immunol Methods, 2004. 290(1-2): p. 51-67.
34. Marks, K.M., M. Rosinov, and G.P. Nolan, In vivo targeting of organic calcium
sensors via genetically selected peptides. Chem Biol, 2004. 11(3): p. 347-56.
35. Meyer, S.C., T. Gaj, and I. Ghosh, Highly Selective Cyclic Peptide Ligands for
NeutrAvidin and Avidin Identified by Phage Display. Chem Biol Drug Des, 2006.
68(1): p. 3-10.
36. Morita, Y., et al., Selection and properties for the recognition of P19 embryonic
carcinoma stem cells. Biotechnol Prog, 2006. 22(4): p. 974-8.
37. Sharma, A., et al., Specific and randomly derived immunoactive peptide
mimotopes of mycobacterial antigens. Clin Vaccine Immunol, 2006.
38. Peelle, B.R., et al., Probing the interface between biomolecules and inorganic
materials using yeast surface display and genetic engineering. Acta Biomater,
2005. 1(2): p. 145-54.
39. Peelle, B.R., et al., Design criteria for engineering inorganic material-specific
peptides. Langmuir, 2005. 21(15): p. 6929-33.
40. Orlitsky, A., N.P. Santhanam, and J. Zhang, Always Good Turing: asymptotically
optimal probability estimation. Science, 2003. 302(5644): p. 427-31.
Chapter 2: Theoretical Limitations for Two-step Pretargeted
Radioimmunotherapy of Avascular Micrometastases
We examine here the theoretical potential of pretargeted radioimmunotherapy
(PRIT) under optimal conditions to kill every cell in malignant avascular
micrometastases. A mathematical model of PRIT was developed that combined a two-
compartment pharmacokinetic model, antibody binding kinetics, diffusion and catabolism
in tumor spheroids, and radiation dosimetry models for alpha- and beta-emitting
radionuclides. An infusion dosing scenario was developed in which the patient is infused
with targeting agent at the beginning of the therapy to ensure complete saturation of
antigen in the micrometastasis with targeting agent. Therapy was modeled using a 55 kDa
bispecific molecule and "Y and 213Bi radionuclides. A sensitivity analysis was performed
to determine the parameters with greatest influence on therapeutic success. It is
theoretically possible to kill every cell in 100 [im radius micrometastases using 9Y- or
213Bi-based PRIT with acceptable toxicity, as described herein. The model is quite
sensitive to certain cell parameters: antigen concentration within the micrometastasis,
void fraction and the radiation dosimetry parameter a. The model is also sensitive to
certain molecular parameters of the targeting agent: the diffusivity and the targeting
agent-antigen association rate. Notably, the model was insensitive to a/1 (a common
measure of radiosensitivity), the targeting agent-antigen dissociation rate, and all
pharmacokinetic parameters. While the qualitative results for "Y and 213Bi were similar,
2 13 Bi performed better overall, with a significantly larger safe therapeutic time window
for dosing radioisotope-carrying hapten. The model results presented here predict that
optimized PRIT protocols and reagents can be used to successfully treat clinically
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undetectable micrometastases. In addition, these results indicate that PRIT may represent
an advantageous use for alpha-emitting radioisotopes in radioimmunotherapy, due to the
short residence time of the radionuclide. The sensitivity analysis identifies key
parameters that should guide the development and use of improved PRIT reagents and
protocols.
2.1 Introduction
Tumor metastasis is the primary cause of mortality for breast cancer patients, but
only a minority of patients have clinically detectable metastases at diagnosis, indicating
that a large fraction of patients have small, undetectable micrometastases at the time of
presentation [1]. Thus, an adjuvant, specific therapy such as pretargeted
radioimmunotherapy (PRIT) would have broad clinical relevance, and could be used in
conjunction with surgery, chemotherapy or localized radiation therapy to eliminate both
the primary tumor burden and dispersed micrometastases.
While antibody-based therapies such as PRIT face significant obstacles in the
treatment of solid tumors, they are attractive options for neutralizing avascular
micrometastases. Transport to micrometastases is significantly more efficient than in
solid tumors [2]; micrometastases are more homogenous, so that cells are more uniformly
susceptible to anti-tumor antibodies; lastly, micrometastases that have no developed
hypoxic cores may not exhibit increased radioresistance.
Several different modeling approaches have been synthesized in order to
theoretically examine PRIT in avascular micrometastases. Sung and colleagues
developed an initial framework for modeling PRIT, which they used to examine both
streptavidin-antibody-fusion-based and antibody-biotin-based pretargeting systems in an
open, two-compartment pharmacokinetic model [3]. That model was combined here with
a model of antibody binding, diffusion and catabolism in tumor spheroids developed by
Graff [4] and Thurber [2], and with radiation dosimetry models for alpha- and beta-
emitting radionuclides developed by Charlton [5] and Leichner [6], respectively.
Presented here is a theoretical examination of the limits of pretargeted
radioimmunotherapy. It is shown that it is possible to use PRIT to kill every cell in an
avascular micrometastasis, using either "Y and 213Bi, without undue systematic
cytotoxicity. The therapeutic window for dosing radiometal chelate hapten that will lead
to complete cell killing has been calculated, and a single-variable sensitivity analysis has
been performed to determine the key parameters within the model, in the context of
generating accurate modeling results, and in terms of using this approach successfully in
the clinic, where parameters will vary significantly from patient to patient. While there is
currently little appropriate data in the literature against which to test the model, this
model provides a framework for future analysis of PRIT approaches and provides several
experimentally testable hypotheses, the testing of which should significantly advance
understanding of PRIT.
2.2 Modeling Methods
For bispecific pharmacokinetics, a two-compartment model is used in which the
plasma and normal tissues can exchange material via transcapillary transport and
lymphatic drainage [3]. The micrometastasis is embedded within and in close contact
with the normal tissue. For the purposes of this model, only one micrometastasis is
considered, but the introduction of additional micrometastases does not change the
analysis significantly, as the amount of bispecific material interacting with the
micrometastasis is small compared to the total amount of bispecific in the body. In
previous PRIT modeling and experimental efforts, the antibody-based targeting agent
was almost always delivered as an intravenous bolus dose. In order for bolus-dosed
bispecific to saturate the micrometastasis, it must be transported into the normal tissue
and completely penetrate into the center of the micrometastases. As detailed by Thurber
[2], the problem of delivering an antibody-based agent can be reduced to two
comparisons: first, the bispecific must reach the center of the micrometastasis before it is
cleared from the plasma (the clearance modulus F, defined by Thurber, must be less than
1); second, the rate of bispecific diffusion into the spheroid must be greater than the rate
of bispecific-antigen complex catabolism, or achieving complete saturation will not be
possible (the Thiele modulus D2 must be less than 1). For an avascular micrometastasis
and two-compartment pharmacokinetics, these two moduli are:
F= R2([a R (1)
6D(AUCAb,nomal ) Abno + Ab+o A B
'2 2A= g ke (2)
D[Ab],0
where R is the radius of the micrometastasis, [Ag] is the antigen concentration in the
micrometastasis, e is the void fraction, ke is the rate of antigen and antigen-antibody
complex catabolism, D is the diffusivity of the bispecific in the micrometastasis, Abn0 is
the initial bispecific concentration in the normal tissue (i.e. the steady-state concentration
during the infusion phase), AbPo is the initial bispecific concentration in the plasma, A, B,
a, and p are biphasic pharmacokinetic clearance parameters, iK is the transcapillary
transport rate constant, and X is the lymphatic clearance rate constant. Base-case values
for the constant parameters are provided in Table 2.1.
The bispecific pharmacokinetics in the plasma and normal tissue are:
Ab,(t) = Abo(Ae -ac + Be-f t) (3)
A (Ae-"-" )' Be- P-A)t - (A B
Ab, (t)-= cAbPo + + Ab,,o - AbP o - + -(4)
where AbP(t) is the concentration of bispecific in the plasma as a function of time, and
Abn(t) is the concentration of bispecific in the normal tissue as a function of time. The
base-case values of the constant parameters are specified in Table 2.1. The
pharmacokinetic parameters (A, B, a and P) were estimated using scaling arguments
from a wide range of pre-clinical animal and clinical human data, as little PK data is
available on 60 kDa antibody-based bispecific molecules in the literature.
Parameter Base-case value Sensitivity range Citation
A 0.9 0.7-0.9
B 0.1 0.1-0.3
a (tl/2a) 5.8 x 10- s-1 (0.33 h) 3.9 - 11.3 x 10 s-1 (0.17 - 0.5 h) [7-16]
P (t1/20) 1.83 x 10-5 s-1 (10.5 h) 1.38 - 2.75 x 10- s-1 (7 - 14)
K 1 x 10 s-' 0.5 - 2 x 104 s-' [3]
X 8.9 x 105 s-1  4.5 - 18 x 10-5 s-1  [3]
D 91 x 10-12 m2/s 10 - 91 x 10-12 m2/s [17, 18]
kon 1 x 105 M's -1  1 x 104 - 1 x 106 Mis-1  [19]
koff 2 x 106 s-' 2 x 107 - 100 x 10 s-  [20]
Rsyn 1.15 x 10-'0  not varied
ke 38.5 x 10 -5 s-1  3.2 ... 77 x 10-5 s-1  [21]
R 100 [m not varied [22]
Agvo, 3 x 10-7 M 1 - 5 x 10-7 M [23]
E 0.3 0.1 -0.3 [2]
a (radio.) 0.2 Gy -1  0.05 - 0.4 Gy -1  [24]
a/1 6 Gy -2  1 - 12 Gy -2  [24]
%' (90Y) 3.00 x 106 s'-1  not varied
Table 2.1. Model parameter values, range used for single-variable sensitivity
analysis, and literature sources.
The concentrations of bispecific, antigen and complex within the micrometastasis
are calculated by numerically solving a system of partial differential equations describing
the diffusion, binding and catabolism in a tumor spheroid. The diffusion and binding of
bispecific and the synthesis and degradation of antigen in a spherical micrometastasis are
governed by the following partial differential equations [20]:
dAbt 1 d r2Abt
-- Ab D r-•(_ dA - konAbtAg + kff B
rtdr\ dr )
S= Ryn 
- koAbtAg + kor B - keAg
dt
dB
=B koAbAg - koB - kB
dt
(5, 6 and 7)
where Abt, Ag and B are concentrations of bispecific, antigen and complex, ko. is the
association rate of the bispecific for the antigen, kff is the dissociation rate of the
bispecific from the antigen, and Ry,, is the rate of antigen synthesis. Base-case values of
the constant parameters are given in Table 2.1. Boundary and initial conditions for the
three partial differential equations given above are required. A Neumann boundary
condition is applied at the center of the micrometastasis, specifying zero gradient at r = 0.
A Dirichlet boundary condition is used at the edge of the micrometastasis, requiring
continuity with normal tissue. Initial states for free bispecific, antigen and complex are
also specified.
dAbI (0,t) = 0 (8)
dr
Abt(r = R,t)= eAb,(t) (9)
Ab,(r,O) = Abno
Ag(r,O) = 0 (10, 11 and 12)
B(r,O) = Ag o
This system of partial differential equations was solved analytically using a
Matlab program that implements the method of lines.
Antigen shedding and down-regulation are not explicitly treated in the model, but
could have small effects on the model results. Shedding is primarily dealt with by using
an appropriate antigen concentration in the micrometastasis - since internalization of the
radionuclide is not required for successful cell-killing, it does not make a great deal of
difference whether the bound antigen is on the surface of the cancer cells or has been
shed into the extracellular matrix. Antigen down-regulation could significantly change
the results of the therapy, as bound complex on the surface of cells in the micrometastasis
is a prerequisite for cell killing. Cancer-specific antigens that are strongly down-regulated
by their complementary antibody-based bispecific would make poor candidates for PRIT.
Conversely, if an antigen existed that was up-regulated by its bispecific, then that
antigen/bispecific pairing would be ideally suited for PRIT, as the increased cell-surface
concentration of antigen would allow increased amounts of localized radionuclide. For
this modeling effort, it is assumed that the antigen is neither down- nor up-regulated by
the binding of the bispecific molecule.
For beta- and low-energy-electron emitters, if the radiometal is evenly distributed
throughout the spheroid then the following analytical expression can be used to calculate
the dose-rate absorbed by the cells in the spheroid:
), (r) = CAO, (r) (13)
where C is the mean activity per unit mass (Bq/kg), A = npEav (np is the number of beta
particles per nuclear transformation and Eav is the weighted average beta particle energy),
and ý,(r) is the absorbed fraction for beta particles, defined as [6]:
e= Gof 1+[l+ d('r)+ d 'r)2 + d3('r)3]e-(d4-1)'r dV (14)
where Go can be calculated from Berger's tables [25], and d,, d2, d3, d4 and [I' are
radionuclide-specific constants. d_4 are fitting coefficients, and [' is the apparent
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absorptions coefficient for beta particles. The constant parameters for 9"Y are provided in
Table 2.2. Leichner demonstrates that !A' can be accurately estimated for any given
radionuclide by:
'-= 0.474Eav-2.0 + 5.80Eav- '  (15)
Leichner's analysis has been validated theoretically and experimentally [26].
Parameter Value
n, 1.000
Eav 0.9367 MeV
d, 0.684
d2 0.114
d3 1.38
d4  1.59
1i' 6.6 cm2/g
Table 2.2. Dosimetry parameters for "Y.
In order to evaluate the absorbed fraction, the integral may be written as
3
=Go k (16)
k-O
with
O = df - V (17)
-) ed4,ur(
-f - dr (p'r)dV (18)
-d44'r2
p,2)= fe-'4r d2(L'r)2dV (19)4,rr
(3) e d4r d3 ('r) 3dV (20)
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These integrals can be evaluated at any point inside or outside of the sphere,
allowing us to calculate an absorbed dose rate at any point desired. Expressions for the
above terms at the center of the sphere are provided below; this analysis is taken directly
from Leichner. As an example, for 90Y, in a 100 plm radius sphere, jp(cent) = 0.0436.
0o(cent)= (1-e - 'a )  (21)
,1(cent)- 1- d4' [-(1+d4'a)e -dP'a] (22)
d42ýt
42(cent)- d [ 2 - (d4'a)2 + 2(d4 a + 1)]e-d4Pa (23)
P3(cent) = d 6 -[6 + d4 a(d42 '2a 2 + 3d41'a + 6)]e- d 4P'a (24)
Alpha-particles differ from beta-particles in that they have a shorter path lengths
(50-80 pm), higher energies (5-8 MeV), and higher rates of linear energy transfer (LET)
(~100 keV/ptm, compared to 0.2 keV/pm for a beta-particle) [27]. Alpha particles must
traverse through the nucleus of a cell, as opposed to the cytoplasm, to lead to cell death
[28]. Alpha-particle dosimetry for avascular spheroids can be calculated as follows: a
radial distribution of radionuclide (either calculated, experimentally determined, or
arbitrarily chosen) is converted into a spatial distribution of alpha-particle decays by
integrating the radioactivity concentration profiles over time [29]. Absorbed dose and/or
cell-killing can be calculated from this decay distribution via Monte Carlo methods [5].
For a radially uniform distribution of 213Bi, Charlton's results are summarized in the
following table.
# 2 13Bi atoms / cell 1 5 8 9 10
spheroid radius (pm)
25 8.20E-01 3.71E-01 2.04E-01 1.68E-01 1.37E-01
37.5 6.70E-01 1.35E-01 4.06E-02 2.72E-02 1.82E-02
50 5.60E-01 5.51E-02 9.67E-03 5.42E-03 3.03E-03
67.5 4.70E-01 2.29E-02 2.38E-03 1.12E-03 5.26E-04
75 4.30E-01 1.47E-02 1.17E-03 5.03E-04 2.16E-04
87.5 3.90E-01 9.02E-03 5.35E-04 2.09E-04 8.14E-05
100 3.70E-01 6.93E-03 3.51E-04 1.30E-04 4.81E-05
112.5 3.40E-01 4.54E-03 1.79E-04 6.07E-05 2.06E-05
Table 2.3. Surviving cell fraction as a function of spheroid radius and
average number of 213Bi atoms per cell (adapted from [5]).
The data in the table above were calculated based on a 50% packing fraction of
cells in the spheroid, and an average radius of 5.88Rm. The number of cells in each
spheroid ranges from 38 (25[tm radius spheroid) to 3502 (112.5xm radius spheroid). For
each spheroid radius, we can calculate the minimum number of 213Bi atoms per cell
required to kill every cell in the spheroid, as shown in the table below.
Cells in Maximum surviving Minimum 213Bi atoms perspheroid Minim Bi atoms perSpheroid radius (m)oid fraction for complete(50% cell for complete killing
packing) killing
25 38 2.63E-02 18.3
37.5 130 7.69E-03 12.2
50 307 3.26E-03 9.9
67.5 600 1.67E-03 8.5
75 1038 9.63E-04 8.2
87.5 1648 6.07E-04 7.9
200 2459 4.07E-04 7.9
112.5 3502 2.86E-04 7.6
Table 2.4. Requirements for complete cell killing.
Note that due to the very high radiotoxicity of 213Bi, only a few atoms of 213Bi per
cell are required for complete killing. If each cancer cell has approximately 100,000
copies of the cancer-specific antigen on its surface, and the radiolabeled fraction of metal
chelate is 0.0025 (both of these estimates are conservative), then saturating the cell
surface antigen with radiometal chelate would deliver at least 250 213Bi atoms to the
micrometastasis, suggesting that substantial overkill is possible in an optimized PRIT
therapy setting. Note also that although Charlton's data only extends to spheroids of radii
1 12.5um, the number of radionuclide atoms required for complete killing decreases with
increasing radius.
The specific activity (decays per second per mass or mole) of the radiometal
chelate is an extremely important variable in therapeutic pretargeting, since it directly
determines the amount of radioactivity that can be localized on the surface or within a
cancer cell. The chart below presents published specific activities for radioisotopes of
interest. Note that to date, while the specific activities are similar, the radiolabeled
fraction of 213Bi conjugates is far lower than for 9Y, indicating that there is substantial
room for improvement.
Isotope Context Specific Activity Fraction Labeled Citation
"Y DPTA-protein 111 MBq/mg -0.1 [30]
213Bi chelate-mAb 236 MBq/mg -0.00274 [31]
Table 2.5. Attainable specific activities for radionuclides of interest.
To calculate tili, the following steps are followed: at each time t, the concentration
of bound bispecific at the center of the micrometastasis is calculated; the bispecific
concentration is lowest at the center of the spheroid, since antigen-bispecific is being
consumed throughout the spheroid but only being replenished via diffusion from the
boundary with the normal tissue. However, until very late times bispecific-antigen
complex concentration actually varies very little with radius; radial complex
concentration profiles as a function of time are shown in Figure 2.1.
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Figure 2.1. Radial concentration profiles of bound bispecific in the tumor
micrometastasis as a function of time. Solid line, 1 hr. Dashed line, 12 hrs.
Dotted line, 24 hrs. Dash-dotted line, 36 hrs.
Making the conservative assumption that the concentration of bispecific-antigen
complex throughout the spheroid is the same as at the center, it is then determined if the
resulting dose from radiometal-bispecific-antigen complex is sufficient to kill every cell
in the spheroid. For beta particles, the absorbed dose is explicitly calculated as detailed
above, and a modified dose-effect relationship is used to determine the surviving fraction
[32]:
S=e f (25)
where dosimetry parameters are defined as above, S is the surviving fraction, V' is the
radioactive decay constant of the radionuclide of interest, and a' and 3' are cell-line
specific radiosensitivity parameters.
For beta particle-emitters, tian is the first time at which the surviving fraction is
greater than I divided by the number of cells in the spheroid. For alpha-particle emitters,
tkn can be simply calculated as the first time at which the concentration of bispecific at
the center of the micrometastasis drops below the concentration corresponding to the
required number of radionuclide atoms per cell, as set forth in Table 2.4. Charlton shows
that such predictions are not particularly sensitive to the spatial distribution of
radionuclide - rather, it is the overall average concentration that is important. As a result,
small stochastic cell-to-cell variations in the number of localized radionuclides need not
be of great concern.
Finally, a single-variable sensitivity analysis was performed by varying each of
the model parameters across its greatest reasonable range, and calculating the size of the
therapeutic window At to determine how it varied as a function of the parameter of
interest.
2.3 Results
The goal of this modeling effort is to determine if it is theoretically possible to kill
every cell in an avascular micrometastasis using PRIT with 90Y and 213Bi with acceptable
systemic toxicity. In order to determine this endpoint, the following steps must be
performed: calculating the concentration of the bispecific as a function of time in the
plasma and normal tissues; calculating the concentration of free bispecific, free antigen
and bispecific-antigen bound complex in the micrometastasis as functions of time and
radius; calculating the time (trD) after bispecific administration that radiometal-carrying
hapten can first safely be administered, and the time (tu,,) after bispecific administration
before which the hapten must be dosed in order to ensure that every cell in the
micrometastasis is neutralized. The duration At = tkll - tro determines the size of the
therapeutic time window for radiometal hapten dosing. If At is positive, then the therapy
can theoretically be successful; if At is negative, then it is not possible to kill every cell in
the spheroid under the specified conditions without exceeding the maximum tolerated
dose (MTD). As a practical matter, At should be maximized, in order to provide reduced
uncertainty for patient safety and ensure complete cell killing via predicted overkill.
These two requirements (MTD and minimum effective dose) for delivering
bispecific to a micrometastasis set strict limits on how much bispecific must be dosed if
saturation is to be achieved, to the point that improbably large bolus antibody doses can
be required to completely saturate the antigen in the tumor with antibody. To address this
problem, and to maximize the potential of PRIT, we propose to use infusion dosing of
bispecific to saturate the micrometastasis. In an infusion dosing scenario, the patient is
infused with bispecific for a sufficient period of time to ensure than all antigen in the
micrometastasis is bound with antibody, circumventing the clearance modulus
requirement. While this may require large amounts of bispecific, the production of such
amounts is certainly achievable, and the steady-state plasma concentration of bispecific is
not unreasonably high (in the hundreds of nanomolar). At the point of complete
saturation (or sometime after), the bispecific infusion is stopped (time t = 0). Bispecific
will clear rapidly from the plasma, less rapidly from the normal tissues, and still less
rapidly from the micrometastasis. Under the right conditions, this will lead to a
therapeutic window in which radiometal hapten can be dosed safely and still lead to
complete killing in the micrometastasis.
A base-case set of modeling parameters was developed using the best available
parameter values from the literature (Table 2.1). The initial bispecific concentration in
the plasma was set at 200 nM, which corresponds to 4D2 = 0.212. According to Thurber's
analysis of antibody penetration into tumor spheroids and our numerical calculations [2],
this concentration is sufficient to ensure near-complete saturation of antigen in the
micrometastasis. Given this initial bispecific concentration, equations 3 and 4 above
were used to calculate the resulting pharmacokinetic profiles, which are presented in Fig.
2.2. As illustrated in Fig. 2.2, the concentration of the bispecific in the plasma drops
quite rapidly, while the concentration in the normal tissue falls less quickly.
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Figure 2.2. Bispecific pharmacokinetics and micrometastasis saturation
calculated using base-case parameter set. Concentration of bispecific in
plasma, solid line. Concentration of bispecific in normal tissue, dashed line.
Concentration of bispecific-antigen complex at center of micrometastasis,
dotted line. Concentration of free bispecific at center of micrometastasis,
dash-dotted line.
The pharmacokinetic parameters a, P~, A and B for a 60 kD protein were difficult
to estimate from the literature, as their values vary widely in animal experiments and
human trials and defied attempts at allometric scaling. This extreme variation may be due
to the fact that a protein of 60 kD is very close to the molecular weight cut-off for
glomerular filtration in the kidneys, which could lead to radically different
pharmacokinetic outcomes as a result of relatively small variations in the actual cut-off
weight in different animals or populations of animals. To determine how important these
pharmacokinetic parameters were to the model, three different sets of pharmacokinetic
parameters were compiled: base-case, fast and slow. The concentration profiles of the
bispecific as calculated using these different parameter sets are presented in the Figures
2.3 and 2.4.
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Figure 2.3. Bispecific pharmacokinetics and micrometastasis saturation
calculated using slow pharmacokinetic parameter set. Concentration of
bispecific in plasma, solid line. Concentration of bispecific in normal tissue,
dashed line. Concentration of bispecific-antigen complex at center of
micrometastasis, dotted line.
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Figure 2.4. Bispecific pharmacokinetics and micrometastasis saturation
calculated using fast pharmacokinetic parameter set. Concentration of
bispecific in plasma, solid line. Concentration of bispecific in normal tissue,
dashed line. Concentration of bispecific-antigen complex at center of
micrometastasis, dotted line.
Next, the expression for bispecific concentration in the normal tissue specified by
equation 4 was used as a time-varying boundary condition to the system of partial
differential equations 5, 6 and 7, in order to calculate the concentrations of free antibody,
free antigen and bound complex in the micrometastases as functions of radius and time.
The concentrations of free antibody and bound complex at the center (r = 0) of the
micrometastasis are also shown in Fig. 2.2. In the micrometastasis, free bispecific
diffusing into the spheroid is rapidly bound by newly synthesized antigen, keeping the
concentration of free antibody in the micrometastasis extremely low. As a result, only
I
the concentration of bound complex needs to be considered to accurately calculate
radiation dosimetry.
While an antibody-based targeting agent such as a bispecific molecule 50-60 kD
in size will encounter significant resistance in passing through the capillary wall, a small
molecule radionuclide hapten will rapidly perfuse all tissues of the body [33]. The initial
plasma concentration of radiometal hapten required to completely bind all remaining
bispecific in the body can be calculated from hapten-bispecific association and
dissociation rates, the antigen turnover rate, and the pharmacokinetic constants for the
hapten. Given the rapid extravasation times of small molecule haptens, it is reasonable to
assume that it is possible to bind every molecule of bispecific in the patient with
radiometal hapten.
The earliest time at which radiometal hapten can be dosed will be a function of
the maximum tolerated dose absorbed by the patient from hapten-bispecific complex that
is located in healthy tissues. The fate of radiometal chelate that binds to circulating (non-
localized) bispecific has not been experimentally determined. Metal chelates alone
generally pass through the kidneys and are eliminated in the urine, resulting in minimal
dose to healthy tissues [33, 34]. On the other hand, directly radiolabeled antibodies,
antibody fragments and peptides are taken up by the kidney, which can lead to
substantial, even dose-limiting nephrotoxicity [35, 36]. Until there is evidence to the
contrary, we should conservatively assume that radiometal chelate bound non-covalently
to antibody-based molecules behaves in the same manner as covalently-linked radiometal
- that is, it is localized to the kidney. The renal accretion of antibody fragments can be
significantly inhibited by administering D-lysine, which can decrease the renal dose by
up to five-fold, increase the maximum tolerated dose, and in some cases change the dose
limiting organ from the kidney to the blood [35].
Experimentally, it has been found that in therapeutic radioimmunotherapy, the
bone-marrow is almost always the dose-limiting tissue, and we expect this to be the case
in PRIT, as well. In a mouse study comparing the efficacy of 213Bi- and 9Y-labeled anti-
tumor Fab' fragments, Behr and co-workers found that with lysine protection, the MTD
of 9OY-Fab' was 9.25 MBq and the MTD of 213Bi-Fab' was 25.9 MBq, with the blood (the
dose-limiting organ) receiving doses of 5-8 Gy. Bone marrow transplantation allowed
increases in MTD to 14.8 MBq of 9Y-Fab' and 40.7 MBq of 213Bi-Fab' [37]. In a Phase
I/II clinical trial of 9Y-Zevalin, the MTD was 11.1 - 14.3 MBq/kg, with most adverse
events being hematologic [38], once again indicating that the bone marrow was the dose-
limiting tissue.
Thus, we can determine to directly by simply determining the time at which the
concentration of bispecific in the plasma drops below the concentration that correlates to
the clinically determined MTD, assuming that all of the bispecific is bound by radiometal
chelate with a maximal specific activity. For example, given a MTD of 12.95 MBq/kg
for antibody-conjugated "Y and a body weight of 90 kg, the MTD of antibody-bound 90Y
is 1.17 GBq. This corresponds to roughly 7 nmol of 9Y-bispecific labeled at 111
MBq/mg. To calculate to, we simply need to determine at what time 7 nmol of
bispecific remains in the body; this is straightforward, and the calculation is similar for
213Bi.
The boundaries of the therapeutic window, tm and tdun, were determined from the
plasma concentration of the bispecific and the concentration of antigen-bispecific
complex at the center of the micrometastasis, as set forth in the Methods above. For the
base case, the 90Y dosimetry calculations led to a tr of 9.2, and tnill of 29.4, giving a
therapeutic window of 20.2. For 213Bi dosimetry, a to of 17.6 and tkll of 79.3 were
calculated, leading the a greater therapeutic window of 61.7. Therapeutic window results
for the slow and fast pharmacokinetic data sets are presented below.
Parameter set 90Y 213Bi
toW tein At toM tkin At
Base-case 9.2 29.4 20.2 17.6 79.3 61.7
Slow PK 34.3 59.5 25.2 45.4 125.8 80.4
Fast PK 6.1 21.7 15.6 11.7 54.5 42.8
Table 2.6. Variation of therapeutic window with fast, slow and base-case
pharmacokinetics. All times in hours.
While the pharmacokinetic profiles vary significantly for the different data sets,
the therapeutic window is notably insensitive to pharmacokinetic parameters, because
both of the window-determining concentration profiles (blood and tumor) shift to
approximately the same degree, keeping the window size approximately constant.
Using the base case analysis as a starting point, a single-variable sensitivity
analysis was performed, with the therapeutic window At being the output. Each
parameter was independently varied across all reasonable and/or relevant values. The
range of each variable is given in Table 2.1. The results of the sensitivity analysis are
presented in Figs. 2.5, 2.6 and 2.7. For the two radionuclides 9OY and 213Bi, the
parameters are grouped into three sets - parameters that are cell-type specific, molecular
parameters of the bispecific molecule, and pharmacokinetic and patient parameters. The
results are presented for each of these three sets.
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As illustrated in Fig. 2.5a, the size of the therapeutic window At is quite sensitive
to certain cell parameters for 9Y-based PRIT. A two-fold change in either antigen
concentration, void fraction or the radiation dosimetry parameter a result in substantial
decreases in the therapeutic window to near or beyond At = 0, the point at which it is no
longer theoretically possible for PRIT to be used to kill every cell in the micrometastasis.
Notably, the model is insensitive to a/If, a traditional measure of radiosensitivity, but is
quite sensitive to a, the radiosensitivity parameter associated with first-pass cell killing
by beta particles. Additionally, as shown in Fig. 2.6a, At is quite sensitive to D and k.,
but insensitive to changes in koff. Lastly, At is remarkably insensitive to variation in
pharmacokinetic parameters for 9Y-based PRIT, as shown in Fig. 2.7a. Even very large
variations in pharmacokinetics do not lead to situations in which 9Y-based PRIT is
theoretically unsuccessful. This is due to the fact that while changing pharmacokinetic
parameters affects the concentration of bispecific in the plasma as a function of time, that
plasma concentration in turn affects the normal and tumor bispecific concentrations. As a
result, the curves that determine t.. and t,,, are shifted in the same direction when
pharmacokinetic parameters are changed, resulting in relatively small changes in the
therapeutic window.
The results are similar for 213Bi, but the therapeutic window remains further above
zero than for 9Y, since At for the base-case for 213Bi is much larger than for 90Y. For the
cell parameters, the model is fairly sensitive to e, as shown in Fig. 2.5b. As it is for 90Y,
the model is very sensitive to changes in D and kon, and insensitive to both changes in kff
and pharmacokinetic parameters for 213Bi, as shown in Figs. 2.6b and 2.7b.
2.4 Discussion & Conclusions
We have shown that it is theoretically possible to use PRIT in an adjuvant setting
to kill every cell in an avascular micrometastasis using either a beta-emitting radionuclide
("Y) or an alpha-emitting radionuclide (213Bi) while maintaining safe doses of
radiometal. In this analysis, 213Bi performed particularly well, with a very large
therapeutic window, indicating both a high degree of confidence in the method since the
large therapeutic window reduces concerns about patient-to-patient variability, and also
possibility to deliver many times the necessary cell-killing dose to the metastasis. Alpha-
emitting radionuclides have been long thought to have great potential in cancer therapy
due to their high radiotoxicity, but their use has been limited as a result of the main
problem of conventional radioimmunotherapy (a poor dose ratio of tumor to healthy
tissue) being exacerbated by the radiotoxicity of an alpha emitter. PRIT may present an
ideal setting for alpha emitters to be used, since they would be in the patients' circulatory
system for only a short time, yet can be effectively targeted to micrometastases where
they can do a great deal of damage.
While the chosen beta-emitter "Y does not perform quite as well as 213Bi, it does
show some promise, both for itself and for other beta-emitting radionuclides. "Y, with a
long path length of 5 mm, is not an ideal radionuclide for adjuvant PRIT, since much of
the radiation emitted by the radionuclide will be deposited outside of the micrometastasis.
Thus, other beta-emitting radionuclides with more appropriate path lengths (such as Ga-
67) may perform even better in this model of PRIT [39].
There are two key features of the approach described here that led to the results
presented. First, the reduction of the key rate processes into Thiele and clearance moduli,
in addition to enhancing understanding of the tumor targeting process, also led us to
employ an infusion, rather than bolus dosing scenario. The infusion dosing scenario,
because it ensures complete saturation of the micrometastasis with bispecific at the
outset, provides optimal conditions for determining the limits of pretargeting.
The sensitivity analysis performed on the results of the model described herein are
the most significant results presented in this work. It revealed the relatively
counterintuitive findings that pharmacokinetic parameters are largely unimportant to the
overall success of failure of the pretargeted therapy. On the other hand, the model is
quite sensitive to cellular parameters, suggesting that molecular-level descriptions of
different cancer types and cell-lines may be extremely useful in determining if PRIT can
be successful for a particular cancer. Parameters specific to the individual patient could
be determined during the imaging dosimetry tests that precede all radioimmunotherapy.
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Chapter 3: Isolation and characterization of gallium-DOTA-
biotin-binding antibodies and peptides
We attempted to isolate high affinity scFv or linear peptide binders against the
loaded metal chelate Ga-DOTA-biotin. A nonimmune library of human scFv fragments
displayed on the surface of yeast was screened using MACS and FACS, and subsequent
yeast-displayed affinity maturation libraries were constructed by VH domain shuffling
and random mutagenesis. These libraries were also screened, but improved scFv mutants
were not isolated. The highest affinity obtained for an scFv against Ga-DOTA-biotin was
in the low micromolar range, and the clones isolated were difficult to characterize. A
linear peptide library displayed on the surface of yeast was also screened for binding to
Ga-DOTA-biotin. Several peptides that bound specifically to Ga-DOTA-biotin were
isolated, but they were strongly positively charged and bound the metal chelate with only
lower micromolar affinity. It is possible that it is difficult to engineer antibody fragments
and linear peptides for binding to Ga-DOTA-biotin due to the chelate's six-coordinate
binding of the gallium ion, which may result in rapid exchange of the carboxyl arms of
the chelate in solution.
3.1 Introduction
An extremely high affinity scFv against carcinoembryonic antigen was developed
by Graff and co-workers [1]. We proposed to use this scFv, called sm3E, as the cancer-
specific half of an optimal bispecific reagent for PRIT. It was then necessary to select a
hapten for use in PRIT, and develop the anti-hapten half of the bispecific reagent.
Our first choice for an optimal hapten was the metal chelate DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), which binds many metal ions with +2
52
and +3 net charges with extremely high affinity [2, 3]. Metal chelates such as DOTA and
DPTA are commonly used for conjugating radioisotopes to antibodies [4, 5]. The
methods used for conjugating DOTA to proteins [6, 7] can be easily adapted to conjugate
DOTA to biotin (which is necessary for fluorescent labeling of DOTA-binding yeast cells
in FACS). Small metal chelates such as DOTA make ideal hapten molecules due to their
very short pharmacokinetic clearance times [8]. Antibodies against metal-loaded DOTA-
derivates had been developed previously [9] and were characterized during the course of
this research [10, 11].
Yeast surface display has been used to isolate and engineer extremely high-
affinity antibodies that bind to both small molecules [12] and protein targets [1, 13, 14].
The main advantage of yeast surface display is that because it uses flow cytometry as its
selection method, selection can be performed in a quantitative manner, making possible
very fine discrimination between mutants with similar properties [15]. In protein
engineering contexts, yeast surface display has proven to be extremely powerful - for
example, it was used to isolate a monovalent antibody fragment against fluorescein with
sub-picomolar affinity [12]. Yeast surface display has also been used to display linear
peptide libraries and select short peptides that bind to patterned surfaces [16, 17].
Finally, high-affinity peptides against small molecule targets have been isolated using
phage display [12]. Based on these encouraging results in the literature, we expected that
it would be possible to use yeast surface display to engineer a high affinity metal chelate
binder. We attempted to isolate a high affinity antibody fragment or peptide that bound
to Ga-DOTA to be used as the hapten-binding part of a PRIT targeting agent.
3.2 Methods
3.2.1 Loading DOTA with metal ions
DOTA (Macrocyclics) and DOTA loaded with Ga3 ÷ by the addition of gallium
nitrate (Sigma) were analyzed using NMR. Metal-free conditions were used throughout
sample preparation and analysis. NMR experiments on 1-2 mM solutions of DOTA and
Ga-DOTA were performed in 90% H20/10% D20, on a Varian Unity 300 MHz
spectrometer, in order to determine if metal loading was successful.
3.2.2 Synthesis, purification and characterization of Ga-DOTA-biotin
DOTA was conjugated to biotin-XX based on the conjugation protocol used by
Keire and co-workers [7]. Biotin-XX, a biotin-derivative with a long linker attached, was
selected so that if the metal-DOTA part of the conjugate was bound deep in the cleft of
an antibody fragment, the biotin moiety would still be accessible for binding by
streptavidin-PE during fluorescent labeling. Synthesis of DOTA-biotin began with the
addition of a solution of 3.6 mg of DOTA and 3 mg of sulfo-NHS in 0.1 mL of H20 to
0.05 mL of a freshly prepared solution of EDC (50 mg/mL). After 30 min, 5 mg of
biotin-XX (Molecular Probes) was added to the reaction mixture, the pH adjusted to 8 w/
11 [L of IM NaOH, and the solution was left overnight. The next morning, the reaction
was quenched by lowering the pH of the reaction mixture to 2 with the addition of 33 pL
of 1 N HCI. The final mixture contained both doubly and singled modified forms of
DOTA-biotin and unmodified DOTA that were separated by reversed-phase
chromatography.
The products of the reaction were purified using a Pharmacia Biotech FPLC
chromatography system equipped with a Source 15RPC stationary phase column
(Amersham Pharmacia Biotech). The purification method used a flow rate of 0.3
mL/min throughout and used a linear gradient from 0 to 100% solvent B over 80 min
(solvent A, 0.1% TFA in H20; solvent B, 0.1% TFA, 10% H20, 90% CH3CN), beginning
28 min after injection. 1.2 mL samples were collected and the absorbance of each was
measured at 214 nm. Peak samples were collected, lyophilized and identified by their
mass-to-charge ratio using mass spectrometry.
Singly-conjugated DOTA-biotin was loaded with Ga3 ÷ in the form of gallium
nitrate according to published protocols for rapidly loading gallium into DOTA [18].
3.2.3 Screening of a yeast-displayed human nonimmune scFv library against Ga-
DOTA-biotin
A nonimmune scFv library displayed on the surface of yeast [14] was screened
for binders against Ga-DOTA-biotin using 1 round of magnetic cell sorting (MACS) and
3 rounds of flow activated cell sorting (FACS). In MACS, 3 x 10' induced cells from the
nonimmune library were resuspended in 10 ml phosphate buffered saline (PBS)
supplemented with 0.1% bovine serum albumin (BSA). Ga-DOTA-biotin as added to the
resuspended cells at 1 [pM final concentration, and the cells were incubated at 40 C for 60
minutes with constant mixing. The cells were then pelleted by centrifugation (3000g for
3 minutes) and washed twice with 10 mL PBS/BSA buffer. The cells were pelleted
again, resuspended in 5 mL PBS/BSA buffer with 100 tiL MACS streptavidin-coated
beads (Miltenyi), and incubated at 40C for 30 minutes with constant mixing.
45 ml of cold PBS/BSA buffer was added to the cell/bead mixture, and the cells
were pelleted by centrifugation as above and washed in 50 m L PBS/BSA buffer. The
suspension was vortexed thoroughly to ensure a single cell suspension, and incubated on
ice for 5 minutes. A Miltenyi LS column was loaded onto its magnetic stand and
pretreated with 7 mL of cold PBS/BSA buffer. 7 mL of cell/bead suspension were added
to the column at a time. After 7 mL of the mixture had entered the column and flow had
stopped, the column was removed from the magnet and then put back in place
immediately, but as gently as possible. The intent of this step is to rearrange the
magnetic beads in the column and allow cells that are physically trapped in the column to
pass through. With the column back in the magnet, an additional 7 mL of cells was
added to the column, and the procedure was repeated until all 50 mL of cells had been
added.
After all cells had been added, the column was washed with 3 mL PBS/BSA
buffer, making sure that the upper loading column was washed of all residual cells. This
wash removes the cells in the void volume of the column. The column was removed
from the magnet, gently replaced, and another 3 ml of cold PBS/BSA buffer was added.
To elute Ga-DOTA-biotin binding cells, the column was removed from the
magnet, 7 ml of SD-CAA media was added to the column, and the plunger was used to
push all remaining cells into a 15 mL conical tube. Regardless of antigen concentration,
2-3 x 107 cells are typically eluted [19]. Eluted cells were grown overnight in 100 mL of
SD-CAA supplemented with a 1:50 dilution of stock penicillin-streptomycin (10,000
units/mL penicillin, 10,000 [Lg/mL of streptomycin) to prevent bacterial contamination.
Cells were grown overnight and induced for subsequent FACS.
Three rounds of FACS were performed on the cell population isolated using
MACS. For all FACS screens, cells were labeled at a concentration of 5 [iM Ga-DOTA-
biotin. FACS was performed as previously documented [1, 12, 14, 15, 20], using anti-c-
myc antibodies to normalize for expression, and using three different secondary detection
reagents - neutravidin-PE, streptavidin-PE, and streptavidin-APC - to prevent the
isolation of scFvs that bind secondary reagents.
A population of Ga-DOTA-biotin binding yeast cells was isolated and
characterized for binding to Ga-DOTA-biotin and unloaded DOTA-biotin. 20 single
clones were cultured and screened using flow cytometry at 2 [LM to determine which
bound most strongly to Ga-DOTA-biotin. The three best clones - 9, 11 and 17 were
characterized in more detail via flow cytometry.
3.2.4 Affinity maturation of Ga-DOTA-biotin-binding scFvs
In order for a bispecific molecule to function successfully in PRIT, it must be able
to retain hapten for long enough so that the antigen-diabody-hapten complex can be
internalized into the cell. Based on typical antigen turnover half-lives of 15-60 minutes,
the hapten-binding part of the targeting agent needs to bind hapten with at least low
nanomolar affinity. Therefore, the affinity of Ga-DOTA-biotin-binding scFvs needed to
be improved by approximately 1,000-fold. Our philosophy in attempting to affinity
mature anti-Ga-DOTA-biotin scFvs was to make larger, domain-level changes early in
the process, followed by smaller, single-residue-level changes later. Consistent with that
philosophy, two libraries were constructed and screened in an attempt to isolate high-
affinity anti-Ga-DOTA-biotin scFvs.
First, a VH-shuffled library was constructed. In this library, the VL domains of a
large pool of binders (population pMF3N) were held constant, and VH domains from the
nonimmune scFv library [14] were swapped in via homologous recombination [21] in an
attempt to find an improved VLVH pairing. The decision to swap out the V, domains of
binding antibodies, rather than the VL domains, was informed by the fact that a VL-Only
mutant of the best Ga-DOTA-biotin-binding scFv maintained its Ga-DOTA-biotin-
binding activity. This is counter to the observation that the VH domain (and in particular
the VH CDR3) is usually most responsible for antibody binding function [22].
To create a VH-shuffled library, plasmid DNA from the population pMF3N was
collected using the Zymoprep method (Zymo Research) and amplified in E. coli. This
DNA was then cut with restriction enzymes Pst I and BamH I to remove the VH region
from the plasmid. The construction and domain-level structure of nonimmune library-
derived plasmids is described by Feldhaus et al [14]. The VH region of the nonimmune
scFv library was amplified from library plasmid by PCR, and the vector (cut plasmid)
and insert (library PCR) were combined by homologous recombination in yeast [21].
The library of yeast-displayed proteins was labeled and sorted as previously described
[14, 15], and the best binders were isolated, sequenced and characterized.
Following the screening of the VH-shuffled library, a library was constructed
using random mutagenesis as previously described [1, 12, 13]. In this library, promising
anti-Ga-DOTA-biotin binding clones were subjected to error-prone PCR in order to
introduce mutations in the genetic code of the antibody fragments. The library was based
on the following material: 35% DNA from pMF3N clones, 5% each from clones 9, 11,
and 17 (the best clones from population pMF3N), 10% of the unsorted VH-shuffled
library discussed above, and 10% each of the VH-shuffled library after 1, 2, 3 and 4
rounds of sorting. The library was constructed by performing error-prone PCR on the
entire scFv gene as previously described, and then transforming that insert and cut
pCTCON2 backbone into yeast using homologous recombination [21]. The library of
yeast-displayed proteins was labeled with Ga-DOTA-biotin and sorted as previously
described [14, 15], and the best binders were isolated, sequenced and characterized.
3.2.5 Screening of a yeast-displayed linear peptide library
Faced with the failure to isolate or engineer high-affinity scFvs that bound to Ga-
DOTA-biotin, we explored to possibility of using a peptide as the hapten-binding part of
the bispecific targeting agent. Peptides with affinities in the low nanomolar range have
been reported [23], so it was possible that a high-affinity Ga-DOTA-biotin binding
peptide could be isolated and engineered. In addition, attempts to isolate anti-Ga-DOTA-
biotin scFvs had led to the isolation of peptide-like molecules, so we hypothesized that a
peptide might potentially be better suited for binding this metal chelate.
A pre-existing linear peptide library composed of amino acid 10-mers [16, 17]
was labeled with 1 [M Ga-DOTA-biotin and sorted via FACS. The diversity of the
starting library was estimated to be 1-5 x 107 transformants. The peptides were displayed
on the surface of yeast in the following format: HA epitope tag-(gly 4ser)3-peptide. Four
rounds of FACS were successfully completed, and specifically binding clones were
isolated, sequenced and characterized. Alanine scanning, in which amino acid residues in
the peptides were changed to alanine residues, were performed on the best binding
clones. The intent of alanine scanning was to determine which residues in the peptide, if
any, were crucial or most important for binding to Ga-DOTA-biotin.
3.3 Results
3.3.1 Characterizing the loading of DOTA with Ga3 using NMR
NMR experiments showed that the presence of bound Ga3' in the DOTA
molecule significantly changed the chemical environment of the hydrogen atoms in the
DOTA chelate, as expected. NMR spectra for unloaded and Ga-loaded DOTA are shown
in Fig. 3.1.
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Fig. 3.1. NMR spectra of unloaded and Ga-loaded DOTA in 10% D20/90%
H20, as measured on a Varian Unity 300 MHz NMR spectrometer.
These results confirmed that the Ga3, ion could be successfully loaded into
DOTA. In addition, they indicate that the environments of the hydrogen atoms in Ga-
loaded DOTA are different than those of Y-DOTA [7], indicating that the two complexes
may have different structures. This is in agreement with the finding that Ga-DOTA and
Y-DOTA analogues do have substantially different structures; Ga-DOTA analogues bind
to the metal ion in a six-coordinate fashion, while Y-DOTA analogues are 8-coordinate in
their binding of the metal ion [24].
3.3.2 Synthesis, purification and characterization of Ga-DOTA-biotin
Singly and doubly conjugated DOTA-biotin were separated via reverse-phase
chromatography. DOTA was detected by measuring the absorbance of each 1.2 ml
sample at 214 nm, and peaks were submitted for analysis by mass spectrometry. The
elution profile and mass spectrometry results are presented in Fig. 3.2.
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Figure 3.2. Elution profiles of unreacted DOTA, and singly and doubly
conjugated DOTA-biotin, as separated by reverse phase chromatography.
DOTA was detected by measuring the absorbances of samples at 214 nm.
Unreacted DOTA and other reactants eluted during the wash step, while singly
and doubly conjugated DOTA-biotin were eluted during the gradient step. Singly-
conjugated DOTA-biotin with the expected theoretical mass-to-charge ratio of 784.4 was
eluted first, followed by doubly-conjugated DOTA-biotin. Singly-conjugated DOTA-
biotin was lyophilized, resuspended in H20, loaded with gallium and then used in
subsequent screening experiments. Ga-DOTA-biotin was stored at 4°C.
3.3.3 Screening of a yeast-displayed human nonimmune scFv library against Ga-
DOTA-biotin
After MACS screening of the nonimmune library, eluted cells were grown
overnight in SD-CAA supplemented with penicillin-streptomycin. The next morning, the
absorbance at 600 nm was measured, and the maximum number of eluted cells (and thus
the maximum diversity of the population) was calculated to be 3.3 x 107 , based on a 3-hr
doubling time for yeast. In the first round of sorting, 1.5 x 108 induced cells that had
been labeled with 1 [pM Ga-DOTA-biotin were sorted. Neutravidin-PE was used to
detect antigen binding. 189,000 cells were collected (population pMF), grown up and
induced for sorting. In the second round of sorting, 4.5 x 10' cells that had been labeled
with 1 [.M Ga-DOTA-biotin were sorted, and streptavidin-APC was used for secondary
detection. 200,000 cells were collected (population pMF2A), grown up and induced for
sorting. In the third and final round of sorting, 3 x 107 cells that had been labeled with 1
ptM Ga-DOTA-biotin were sorted, and neutravidin-PE was used for secondary detection.
30,000 cells were collected (population pMF3N). Note that in each round of sorting,
both the biotin-binding protein and the dye used for secondary detection were changed
from what had been used in the previous round, in order to prevent the isolation of clones
that bound to the secondary reagents, rather than Ga-DOTA-biotin. Dot-plots from each
round of sorting are shown in Fig. 3.3.
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Figure 3.3. Dot-plots from three FACS sorts against Ga-DOTA biotin. (a)
Post-MACS population, negative control (all labeling reagents added except
for Ga-DOTA-biotin). (b) Post-MACS population labeled with 1 tM Ga-
DOTA-biotin, first tube of cells. (c) Post-MACS population labeled with 1
ptM Ga-DOTA-biotin, second tube of cells. (d) Population pMF, negative
control. (e) Population pMF, labeled with 1 pM Ga-DOTA-biotin. (f)
Population pMF2A, negative control. (g) Population pMF2A, labeled with 1
iM Ga-DOTA-biotin. The 30,000 cells collected in this sort comprise
population pMF3N.
In each round of sorting, the lack of double-positive cells in the negative control
indicates that the fluorescence of the labeled cells is Ga-DOTA-biotin-specific.
The binding of the population pMF3N was titrated against varying concentrations
of Ga-DOTA-biotin. As shown in Figure 3.4, it was not possible to reach the upper limit
of fluorescence with this population by increasing the concentration of Ga-DOTA biotin,
making it difficult to estimate a Kd for the population.
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Figure 3.4 Titration of binding of population pMF3N displayed on the
surface of yeast to Ga-DOTA-biotin. Mean fluorescence of displaying cells
(as gated by c-myc labeling) is reported (squares). Negative control is an
irrelevant yeast surface-displayed protein fusion (circles).
However, it was possible to show that the binding of the clones in population
pMF3N to Ga-DOTA-biotin was dependent on the presence of gallium. As shown in Fig.
3.5, population pMF3N does not bind to unloaded DOTA-biotin. Also note that at high
concentrations of Ga-DOTA-biotin, almost all of the displaying cells in the population
exhibit some level of binding.
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Figure 3.5. Binding of population pMF3N to Ga-DOTA-biotin is dependent
on the presence of gallium. On the left, population pMF3N is labeled with 5
pM unloaded DOTA-biotin, and on the right, pMF3N is labeled with 5 pM
Ga-DOTA-biotin. In the absence of gallium, the population does not bind to
the metal chelate. Dot-plots are shown at the top, and histogram plots of
binding-associated fluorescence are shown at the bottom. Labeling for
display was performed using 12CA5, an antibody which binds to the HA tag.
Twenty single clones were isolated from population pMF3N for further
characterization and analysis. Each of these clones was grown up, induced and labeled
with 2 [.M Ga-DOTA-biotin, in order to determine which clones bound Ga-DOTA-biotin
with the highest affinity. The results of that cytometry experiment are shown in Fig. 3.6.
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Figure 3.6. Single clone analysis. Twenty clones from population pMF3N
were labeled with 2 pM Ga-DOTA-biotin to assess their binding ability. TheHA tag was used to normalize for expression.
Titrations were performed on clones 9, 11 and 17 in an attempt to determine the
dissociation constants of these scFvs for Ga-DOTA-biotin. Unfortunately, as was the
case for the population as a whole, it was not possible to determine the Kd Of these clones
for Ga-DOTA-biotin, because the fluorescent signal of the labeled cells increased without
end as more Ga-DOTA-biotin was added. However, it was estimated that the binding
was approximately single-digit micromolar. These titrations are shown in Figure 3.7, and
Figure 3.8 presents further labeling data for the best binding clone, 17.
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Figure 3.8 presents further labeling data for the best binding clone, 17.
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Figure 3.7. Titration of Ga-DOTA-biotin binding of clones 9 (diamonds), 11
(circles) and 17 (squares) from population pMF3N.
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Figure 3.8. Mixed titration data for the binding of clone 17 to Ga-DOTA-
biotin. Squares are circles are from experiments performed on different
days but from the same induced yeast culture.
At this point, we decided to attempt to affinity mature these anti-Ga-DOTA-
biotin-binding scFv clones in an effort to improve the affinity enough that it could be
accurately measured using flow cytometry.
3.3.4 Affinity maturation of Ga-DOTA-biotin-binding scFvs
A VH-shuffled library was constructed via in vivo homologous recombination [21]
in yeast by combining the plasmid DNA of population pMF3N with the VH domain
removed with the amplified VH domain of the nonimmune scFv library [14]. The
diversity of the library as measured by the number of yeast transformed was 2 x 105. The
library was labeled with Ga-DOTA-biotin and screened as described above, as shown in
Fig. 3.9. After four rounds of sorting, single clones were isolated and characterized.
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Figure 3.9. Screening a Va-shuffled scFv library based on the VL-regions of
clones in population pMF3N for improved binders to Ga-DOTA-biotin. In
each dot-plot, display of expressed proteins correlates with the x-axis, while
binding of expressed proteins to Ga-DOTA-biotin or secondary reagents
correlates with the y-axis. Top left, the unsorted Va-shuffled library, labeled
with all reagents except Ga-DOTA-biotin. Top right, the unsorted Va-
shuffled library, labeled with 1 pM Ga-DOTA-biotin in addition to other
reagents. Clones binding to Ga-DOTA-biotin are double positive. Bottom
left, the Vs-library after two rounds of sorting, labeled with all reagents
except Ga-DOTA-biotin. Bottom right, the VH-shuffled library after two
rounds of sorting, labeled with 500 nM Ga-DOTA-biotin in addition to other
reagents. Clones binding to Ga-DOTA-biotin are double positive. Note that
by the third round of sorting, clones that bind to Ga-DOTA-biotin only label
for display in the presence of Ga-DOTA-biotin.
Several individual clones were isolated from the screening of the VH-Shuffled
library by FACS. These clones bound Ga-DOTA-biotin with affinities in the low
micromolar range - in order words, the affinity of the clones had not been improved by
performing the VH domain shuffle. In addition, the isolated clones exhibited a peculiar
behavior - as shown in the bottom panels of Fig. 3.9, the cells expressing Ga-DOTA-
biotin-binding scFvs could only be labeled for display (fluorescence on the x-axis) when
they were also labeled with Ga-DOTA-biotin (fluorescence on the y-axis). This strange
phenotype indicated that the c-myc epitope tag being used to label the proteins for display
might in some way be involved in the Ga-DOTA-biotin binding event. In any event, as
the clones isolated from the VH-shuffled library were not improved in affinity, and had
developed a peculiar display phenotype, further affinity maturation was necessary.
A random mutagenesis library was constructed using error-prone PCR on the
following DNA templates: 35% DNA from population pMF3N, 5% each from clones 9,
11 and 17 (the three best clones isolated from pMF3N), and 10% each from the VH-
shuffled library after 0, 1, 2, 3 and 4 rounds of sorting against Ga-DOTA-biotin. Five
transformations via homologous recombination [21] were performed, and 4-5 x 10I
transformants were obtained per shock, for a total starting diversity of 2.2 x 106. After
three rounds of sorting at 250 nM Ga-DOTA-biotin, single clones were isolated and
characterized.
The three best Ga-DOTA-biotin-binding clones isolated from the mutagenic
library were clones m14, m18 and m20. Like previous clones isolated from both the
nonimmune and VH-Shuffled libraries, they were only approximately micromolar in
affinity for Ga-DOTA-biotin, indicating that their binding had not been improved, as
shown in Fig. 3.10.
250
200
150
100
50
0
10 8 10 -7 10-6 10-s
[Ga-DOTA-biotin] M
C,
0.CO
0
C,
CU0oe-
>,
cJ
--
U-0C._1
LJ)
O
E3m18
0 m20
O0o
o 0
0 0
o o
Fig 3.10. Binding of three best clones isolated after three rounds of sorting
from a mutagenic scFv library based on Ga-DOTA-biotin-binding clones.
The KIs of the clones for Ga-DOTA-biotin could not be calculated, but they
are estimated to be in the low micromolar range.
Worse yet, upon sequencing the clones it was discovered that rather than full-
length scFvs, all three best clones were truncated antibody fragments that resulted from
frameshift mutations. In each of the clones, a frameshift mutation in the VL domain
resulted in an overwhelming positively-charged peptide-like region at the C-terminal end
of the protein. This group of positive charges was likely interacting in a weak,
nonspecific way with the negatively-charged carboxyl groups on Ga-DOTA-biotin. At
this point, we began to consider other options for obtaining Ga-DOTA-biotin binding
molecules, as screenings of a nonimmune library and two subsequent affinity maturation
libraries had not isolated or improved binders against the metal chelate.
3.3.5 Screening of a yeast-displayed linear peptide library
A library of linear peptides displayed on the surface of yeast underwent four
rounds of FACS screening in an attempt to isolate high-affinity binders to Ga-DOTA-
biotin. The diversity of the starting population was roughly 1-5 x 107, and its amino acid
composition has been previously described [16, 17]. After four rounds of sorting with
labeling at 1 [tM Ga-DOTA-biotin, enriched populations of peptide binders were isolated,
as shown in Fig. 3.11.
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Figure 3.11. The isolation of anti-Ga-DOTA-biotin linear peptides via
FACS. Top row, fourth round of FACS screening on population 3A. Left,
all labeling reagents except for Ga-DOTA-biotin. Right, 1 RM Ga-DOTA-
biotin and other labeling reagents. Bottom row, fourth round of FACS
screening on population 3B. Left, all labeling reagents except for Ga-DOTA-
biotin. Right, 1 [tM Ga-DOTA-biotin and other labeling reagents.
13 individual clones that bound Ga-DOTA-biotin were sequenced, and 7 unique
peptide sequences were determined, as shown below in Fig. 3.12. Almost all of the
peptides isolated are overwhelming positive in charge at pH 7 (4 of the 7 peptides have
net charges of +5 or greater).
5A-1 RRK CTK KY VSNY
5A-2 TV GL GRPCE Y PP
5A-4 R C RVMW GPRPSQ
5B-2 A R G R R G R R W S R C S
5B-3 RRGPRRGKRKPY
5B-4 P V P C R K R K C R W G
5C-5 Q E A D G G V K T S F S
Figure 3.12. The sequences of seven unique Ga-DOTA-biotin-binding
peptides. All sequences were preceded by ASQGGGGSG, where AS is the
Nhe I restriction site and the rest of the leader sequence is a linker region.
To gain a greater understanding of how these peptides were interacting with Ga-
DOTA-biotin, alanine scanning was performed. Site-directed mutagenesis was used to
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change, individually, each amino acid residue of interest (R, W, C, P or K) to alanine in
the two best binding peptides, 5B-2 and 5B-3. Each mutant was sequenced to verify the
correct DNA sequence, and then labeled with Ga-DOTA-biotin to determine if the
mutation had affected the ability of the peptide to bind Ga-DOTA-biotin. Remarkably,
none of the alanine scanning mutants significantly affected Ga-DOTA-biotin binding,
indicating that no single residue in either of the peptides in question was crucial for
binding.
3.4 Conclusions & Discussion
Libraries of scFvs and linear peptides were screened on the surface of yeast in an
attempt to isolate high affinity (nanomolar or better) binders of Ga-DOTA-biotin.
Unfortunately, this effort was unsuccessful. Binders isolated from a nonimmune scFv
library and subsequent VH-Shuffled and random mutagenesis affinity maturation libraries
had at best low micromolar affinity for Ga-DOTA-biotin. These mutants seem resistant
to affinity maturation, as several different approaches failed to improve binding. For one
set of mutants, binding was depending on the presence of the epitope tag c-myc and anti-
c-myc antibodies; for another set, binders initially thought to be scFvs turned out to be
peptide-like truncations of full-length scFvs that ended in strongly positive polypeptide
regions. In addition, screening of a linear peptide library against Ga-DOTA-biotin also
led to a set of overwhelmingly positively-charged peptides.
Alanine scanning performed on the positively-charged peptides indicates that no
single residue is important in the binding interaction with Ga-DOTA-biotin. It seems
likely that the binding interaction is mediated by nonspecific electrostatic interactions
between the positively charged peptides and Ga-DOTA-biotin, which has regions of
negative charge. Such interactions are not particularly amenable to improvement through
random mutagenesis or other means of affinity maturation.
As discussed earlier in the chapter, when binding Ga3÷ ion DOTA is though to be
six-coordinate. Those six points of binding are the four cyclic nitrogens, and two of the
carboxyl arms, leaving two carboxyl arms free and in solution. Even when DOTA is
conjugated to biotin, one of the arms remains free. We hypothesize that this free arm
rapidly exchanges with the carboxyl groups that are binding the metal ion. While this
exchange does not result in the release of the metal ion from the chelate, it may result in a
continually changing structure of Ga-DOTA-biotin in solution, which could make
isolating binders against the conjugated metal chelate quite difficult. This is opposed to a
molecule such as Y-DOTA-biotin, in which all of the carboxyl arms are directly involved
in the 8-coordinate binding of the metal ion. We believe that it may be easier to isolate
binders against 8-coordinate forms of metal-chelate complexes, as has been previously
accomplished [10]. However, as discussed in Chapter 5, it may be more useful to design
and use in PRIT studies a targeting agent that binds to a small molecule to which any
given radioisotope of interest can be conjugated.
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Chapter 4: The application of asymptotically optimal
probability estimation to protein engineering
In protein engineering, it is very desirable for a researcher to be able to estimate
the number of clones in an enriched population of protein clones with specific desirable
properties, and to be able to determine how many clones must be characterized in order to
discover all unique clones within the population. Asymptotically optimal probability
estimation provides us with a tool that can be used to accurately estimate the total number
of unique elements (including unseen elements) from a small sample of data. We have
combined asymptotically optimal probability estimation with numerical bootstrapping
and non-linear curve fitting to make accurate predictions of the actual diversity of
populations with different types of underlying probability distributions. The advantages
and limitations of this method are discussed with a focus on practical, protein engineering
applications.
4.1 Introduction
In display-based protein engineering, proteins are interest are physically linked to
their genotypes. This is typically accomplished by expressing the protein on the surface
of an organism (such as phage [1] or yeast [2]) containing the gene coding for the protein,
but it can also be accomplished by physically linking the mRNA that codes for the
protein to the expressed protein itself [3]. Typically, large libraries of proteins are
designed and constructed with the goal of selecting a particular clone with desirable
properties from the library. These libraries can either be based upon an existing wild-
type protein that needs to be improved in some way, or the library can be nonimmune,
77
meaning that it is not derived from any particular clone, nor is it biased towards a
particular sequence or family of sequences.
Once a library of candidate proteins has been assembled, constructed and
displayed - no small task in and of itself [4] - it is necessary to screen the library to
identify clones with desirable properties such as improved affinity, stability, or catalytic
activity. For yeast surface-displayed libraries, this is accomplished by flow activated cell
sorting (FACS); for phage and ribosome/RNA display, physical panning is used. In a
typical screening process, several rounds of enrichment for desirable clones are
performed. After the first round (in which the unscreened library is screened), selected
clones are amplified and subjected to further rounds of screening, often under
increasingly stringent conditions. The goal of these further rounds of screening is to
amplify and isolate the most desirable clones within the library.
After multiple rounds of screening, a successful screening process will yield a
highly enriched population of improved protein clones. From a starting library size of
106-1012, a small number (perhaps 10-1000) of the very best clones will have been
isolated. Given the time, effort and financial resources that have been invested into the
library creation and selection process, it is in the best interest of the researcher to know as
much as possible about this pool of improved proteins. In addition, it is useful to isolate
as many of the clones within the pool as possible, as individual clones may possess
desirable properties other than the one screened for that might make them more or less
favorable for whatever final application they are intended. For example, antibodies that
bind with very high affinity to a particular target might have different association and
dissociation rates, thermostabilities, or isoelectric points. Some might have more
potentially immunogenic amino acid changes from germline, and some might be easier to
produce in large quantities. For all of these reasons, it is very desirable for a protein
engineer to be able to both estimate the number of clones in an enriched population, and
then isolate as many of those clones as possible.
The current method for estimating the total underlying diversity of an enriched
population has been used for thousands of years in a wide range of human pursuits: it is
guessing. A protein engineer knows that there cannot be more clones in the population
that the number of phage or yeast collected in the last round of enrichment, but this upper
bound is typically in the tens of thousands, if not higher. Some basic deduction can be
performed: for example, if 20 clones are sequenced and all are unique, then the diversity
of the enriched population is likely "high". Similarly, if 20 clones are sequenced and
only 2 unique clones are identified, the underlying diversity is probably "low". However,
more complicated intermediate situations will defy even the most ingenious researcher's
intuition. This is not surprising - estimating the probability distribution, including
unseen elements, from an incomplete sample set of data is a difficult task. Fortunately,
mathematical tools called asymptotically optimal probability estimators have been
developed to address precisely such a problem.
Probability estimators, which estimate a probability distribution - including
unseen elements - from a sample of data, were first studied by Laplace [5], and improved
upon substantially by Good [6] and Turing, who used probability estimation to crack
German cryptography codes during World War II. Any probability estimator takes as
input a sample of data from a population, and associates with that sample a probability
over the set of unique elements in the sample, plus "new" (as yet unseen elements).
Recently, Orlitsky and co-workers developed a metric (called attenuation) to
mathematically assess the performance of different probability estimators [7]. This
advance allowed them to devise new asymptotically optimal estimators. In this context,
asymptotically optimal means that as more data is sampled, the estimators do not
underestimate the probability of any particular sequence of selected elements. This is a
property that the best previous estimator, developed by Good and Turing, does not
possess.
We propose to apply the mathematical tool of asymptotically optimal probability
estimation to the problem of diversity estimation that is constantly encountered in protein
engineering. Asymptotically optimal probability estimation is ideal for situations in
which the number of possible elements in large in relation to the sample size, and this is
often the case in protein engineering. Orlitsky and co-workers developed two different
asymptotically optimal estimators, referred to as the 2/3 and 1/2 estimators. While the
1/2 estimator is mathematically more optimal, it is more complex to implement and
requires a rapidly increasing number of mathematical operations as the number of
elements in a sample increases, to the extent that running an estimator program based on
the 1/2 estimator would very likely overwhelm the processor and memory capacities of
modern personal computers. For this reason, the 2/3 estimator, which is computationally
more efficient and requires only a constant number of operations per unique element, is
used throughout. For comparison's sake, we have also employed the Good-Turing
estimator and a modified add-one estimator as they are defined by Orlitsky and co-
workers.
4.2 Modeling Methods
The modified add-one, Good-Turing and Orlitsky 2/3 estimators as defined by
Orlitsky and co-workers [7] were implemented in MATLAB. In this work, we will adopt
terminology used by Orlitsky and co-workers. A sample drawn from a population is a
pattern. Each item drawn to form the pattern is an element. Each unique element in a
pattern or population is a symbol. The multiplicity of a symbol is the number of times it
appears in a pattern. For the example, the sequence abacaca is a pattern with seven
elements and three symbols, and the multiplicities of a, b and c are 4, 1 and 2,
respectively. Finally, we add the following term: the diversity of a population is the
number (actual or predicted) of symbols in the population.
All populations used for these simulations have an actual diversity of 100. Three
different probability distributions were used to generate patterns: uniform, normal with a
variance of 10, and dominant. In the dominant distribution, one symbol occurs 40% of
the time, and the remaining 60% of the probability is uniformly distributed among the
remaining 99 symbols. The dominant distribution is considered because it is a situation
which sometimes arises in protein engineering contexts.
4.2.1 Numerical bootstrapping of estimates
Numerical bootstrapping is a method for estimating distribution properties (such
as mean, standard deviation or confidence intervals) of the result of an algorithm applied
to a set of data [8]. In our case, for each pattern selected, an estimator will generate a
single estimate of the underlying diversity of the population from which the pattern was
sampled. Numerical bootstrapping assumes that the data in the pattern approximately
represents the actual population, and then resamples the data in the pattern to estimate the
mean (and other statistics) of the diversity estimate for that particular pattern.
The mean bootstrapped diversity estimate for a particular pattern and estimator
combination was calculated as follows: the pattern was resampled with replacement to
generate 250 resampled patterns. From each of these patterns, the diversity was
estimated using the estimator of interest. The mean and other statistical measures were
calculated for this distribution of diversity estimates.
To determine the ideal resampling number (that is, the number of elements r
selected with replacement from the n elements in the pattern; r can be less than, equal to,
or greater than n), we calculated the mean bootstrapped diversity for a range of r/n ratios,
while varying n as a proportion of the underlying diversity d. The analysis was
performed for each of the three different types of probability distributions used.
4.3 Results
4.3.1 Evaluating accuracy of estimators
To test the accuracy of the three estimators considered, patterns of size n were
drawn from populations with uniform, normal and dominant distributions. For each
pattern, each estimator was used to estimate the underlying diversity of the population
being sampled. The mean diversity predicted averaged over 500 patterns was plotted
against the varying pattern size n for each estimator/distribution combination, as shown
in Figs. 4.1, 4.2 and 4.3.
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Figure 4.1. Mean diversity vs. number of elements in pattern, uniform
distribution. Underlying diversity = 100. Number of unique elements drawn
after 1000 = 100. Each point is the average of 500 runs. Error bars are 2 a,
and are shown for every third point in each curve for clarity.
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Figure 4.2. Mean diversity vs. number of elements in pattern, normal
distribution, variance = 10 (as shown in the inset). Underlying diversity =
100. Number of unique elements drawn after 1000 = 57. Each point is the
average of 500 runs. Error bars are 20, and are shown for every third point
in each curve for clarity.
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Figure 4.3. Mean diversity vs. number of elements in pattern, dominant
distribution. Underlying diversity = 100. Each point is the average of 500
runs. Error bars are 20, and are shown for every third point in each curve
for clarity.
As shown in Fig. 4.1, though both the Orlitsky 2/3 and Good-Turing estimators
eventually hone in on the actual underlying diversity, the Orlitsky estimator approaches it
much more quickly, and with a smaller variance. In Fig. 4.2, the results are quantitatively
different. An underlying normal distribution with a variance of 10 means that an
extremely large number of elements will need to be sampled to discover all 100 unique
elements in the underlying population. The estimators reflect this reality, and converge
on the number of elements that are accessible to them in patterns of reasonable size.
Note that after 1000 elements have been sampled, on average only 57 unique elements
have been discovered. In Fig. 4.3, the accuracy of the estimators in estimating the
diversity of dominant distributions is demonstrated. For the dominant situation, the
diversity predicted by the estimators rises in conjunction with the number of unique
elements discovered.
4.3.2 Numerical bootstrapping of estimates
To determine an ideal resampling ratio r/n for numerical bootstrapping, we
calculated the mean bootstrapped diversity (averaged over three randomly selected
patterns) for a range of r/n ratios, while varying n in proportion to the underlying
diversity d. This analysis was performed for the Orlitsky 2/3 and Good-Turing estimators
each of the three different types of probability distributions used and is presented below
in Fig. 4.4.
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Figure 4.4. Determining the optimal resampling number for the Orlitsky 2/3
and Good-Turing estimators. The mean bootstrapped diversity is plotted as
a function of r/n, where r is the number of elements selected with
replacement from the n elements in the pattern for bootstrapping
calculations. Top row, Orlitsky 2/3 estimator. Bottom row, Good-Turing
estimator. Left column, uniform distribution. Center column, normal
distribution (variance 10). Right column, dominant distribution. Dashed
line, n = 0.5d (where d is the actual underlying diversity); solid line, n = d;
dotted line, n = 1.5d.
Based on the results in Fig. 4.4, a r/n ratio of 1 was selected for all bootstrapping
calculations. This makes sense on an intuitive level, as well - the estimators will perform
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most accurately when provided with all of the data in a pattern, but without artificially
over-representing the selected elements during bootstrapping calculations (as would be
the case if r/n > 1).
4.3.3 Making estimates from a single set of data
In order to be useful for research, asymptotically optimal probability estimation
must be able to make good predictions of the underlying diversity of a population from a
single, particular pattern. We calculated the bootstrapped diversity estimate, non-
bootstrapped diversity estimate, and the number of symbols discovered for a particular
pattern of increasing n, using each of the three different estimators. The results of these
calculations for uniform underlying distributions are shown in Figs. 4.5, 4.6 and 4.7.
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Fig 4.5. Convergence of bootstrapped diversity estimates using Add-One
estimator. Resampling size = number of elements sampled. Uniform
distribution, underlying diversity = 100. Error bars = 2o.
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Fig 4.6. Convergence of bootstrapped diversity estimates using Good-Turing
estimator. Resampling size = number of elements sampled. Uniform
distribution, underlying diversity = 100. Error bars = 2o.
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Fig 4.7. Convergence of bootstrapped diversity estimates using Orlitsky 2/3
estimator. Resampling size = number of elements sampled. Uniform
distribution, underlying diversity = 100. Error bars = 20.
As shown in Fig. 4.5, while the modified Add-One estimator rapidly approaches
the actual diversity of the population (100), it overshoots that value and converges on a
mean diversity of roughly 120. The bootstrapped mean diversities predicted by the
Good-Turing and Orlitsky 2/3 estimators, on the other hand, asymptotically approach the
actual underlying diversity of the sampled population. Thus, numerical bootstrapping
provides a means of transforming the somewhat erratic (but, as shown in Figs. 4.1, 4.2
and 4.3, on average accurate) predictions of the estimators into smooth, predictable
curves that asymptotically approach the true diversity.
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4.3.4 Estimating the underlying diversity by fitting estimator data
The data presented in Figs. 4.5, 4.6 and 4.7 shows the asymptotic progression of
probability estimates as more elements are sampled in a particular pattern. Can we
estimate the asymptotic value (the underlying actual diversity) before actually
discovering all of the unique elements in the population? To accomplish this, a pattern of
size n was selected from a uniform distribution, and the mean bootstrapped diversity was
predicted, as indicated by the X on Fig. 4.8. Next, the preceding part of the asymptotic
curve was calculated by drawing subsets of the selected pattern without replacement, and
calculating the mean bootstrapped diversity at each fraction of n, as indicated by the
empty squares. Finally, this data was fitted using a non-linear least squares method to an
equation of the form f(n) = A(1-e-mn), where A is the asymptotic value of the mean
bootstrapped diversity and m is a coefficient related to how quickly the curve is
approaching the asymptote. The coefficient m can be used to calculate how many
additional elements must be drawn in order to discover all (or, some arbitrary percentage
thereof) of the unique elements in the population.
120
100
I-
S80
00 00.C 60
00M 40
20
n
30 60 90 120 150 180 210 240 270 300
Elements sampled
Figure 4.8. Estimating underlying diversity from a single sample by fitting
estimator data. A pattern of 100 elements containing 70 unique elements
was randomly selected from a uniformly distributed population with
underlying diversity of 100. The mean bootstrapped diversity estimate was
calculated using the Orlitsky 2/3 estimator for 30, 40, ... 90, and 100
elements from the pattern (drawn without replacement and averaged over
three selections), and that data was fitted to an equation of the form f(n) =
A(1-e-'). Highest possible and lowest possible curves are also plotted based
on 95% confidence interval values for A and m.
In Fig. 4.8, while only 70 unique elements from the actual 100 have been selected,
this method predicts a diversity of 112, which is reasonably close to the actual value.
Furthermore, this method is generalizable to other underlying distributions, and the
predicted diversity improves as more elements are sampled. A summary of the results
from other probability distributions is presented in Table 4.1.
Uniform Unique elements in pattern Predicted diversity
n= 100 70 112
n = 200 87 94
n = 300 96 95
Normal
n = 100 35 35
n = 200 40 38
n = 300 45 43
Dominant
n= 100 50 82
n = 200 76 91
n = 300 87 94
Table 4.1. Performance of Orlitsky 2/3-based diversity estimation for
different underlying probability distributions. n is the number of elements
selected.
As shown in Table 4.1, the diversity estimation algorithm employed here - in
which bootstrapped mean diversity estimates are fitted to an exponential function to
estimate the actual underlying diversity - gets closer to the actual underlying diversity
(which, here, is always 100) with the addition of additional data. The attentive observer
will note that in some situations, such as for n = 300, uniform distribution and n = 200 or
300, normal distribution, the estimated diversity is less than the actual number of unique
elements in the pattern. Obviously, the actual diversity must be at least equal to the
number of unique elements in the selected pattern, so these results are artifacts of the
fitting function. However, for uniform and dominant distributions, they are useful
artifacts - when the predicted diversity is approximately equal to (or even slightly less
than) the unique number of elements in the pattern, nearly all of the elements in the
population have been sampled.
Populations with normal distributions present a different situation, however. For
normal distributions with tight variances (such as used here), a very large number of
elements will have to be drawn before all of the unique elements in the population are
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discovered. As a result, the diversity estimation method employed here significantly
underestimates the underlying diversity of the population, simply because it (and the
researchers selecting the elements) cannot gain access to the majority of the necessary
information without drawing extremely large numbers of elements. It is in the interest of
any user of this algorithm to perform a statistical analysis on their selected data to
determine if the underlying probability distribution is uniform, normal, dominant, or
some intermediate distribution, as this will aid in interpreting the diversity estimation
results.
4.4 Conclusions & Discussion
We have developed a method for estimating the underlying diversity of a
population based on an incomplete sample set of data from that population. The method
combines the numerical methods of asymptotic probability estimation, numerical
bootstrapping and non-linear least squares fitting to predict the diversity of a population
with reasonable accuracy. While the method at times returns artifactual results, it is far
more accurate and informative than guessing, the method currently used to tackle this
problem. We expect that this method will be useful for protein engineers in interpreting
their own screening results, and the code and executable programs associated with this
algorithm will be posted online so that they can be used by other researchers.
The diversity estimation method employed here performs best (that is, it correctly
estimates the underlying diversity of a population with the smallest amount of data) for
populations that have uniform distributions of symbols. It also performs quite well for
dominant distributions, in which one symbol represents a large fraction of the elements in
the population, but the other symbols are uniformly distributed. However, this method
does not perform very well for normal distributions with narrow variances, since in this
situation some symbols are so overrepresented in selected patterns that it is very difficult
to ever see most of the symbols in the population. For these reasons, it will be very
useful for researchers using the algorithm to determine the expected or actual type of
probability distribution in the population, as this will aid significantly in interpreting the
results of this method.
Future work on this method will aim to incorporate additional statistical analysis
of the pattern submitted (for example, to determine if it is roughly uniform or normal, as
discussed above), and to alter the algorithms used so that the method does not return
nonsensical results (such as predicting a diversity less than the unique number of
elements already discovered under certain circumstances). Even in its present form,
however, this diversity estimation method should be of substantial practical use to
working protein scientists.
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Chapter 5: Construction, production and characterization of
an anti-CEA, anti-fluorescein single-chain bispecific diabody
An anti-CEA, anti-fluorescein single-chain bispecific diabody was designed based
on the variable domains of anti-CEA scFv sm3E and anti-fluorescein scFv 4M5.3. The
diabody was secreted in S. cerevisiae, and purified using anti-FLAG affinity
chromatography and size exclusion chromatography, for a final yield of 80 [tg / L. The
full-length diabody (55 kDa) binds CEA expressed on the surface of colorectal cancer-
derived SW1222 cells with an a Kd of 4.3 - 2.5 nM, and also binds fluorescein while
bound to CEA on the cell surface. This novel reagent should be useful for future PRIT
preclinical studies, and as a framework for even better PRIT targeting agents.
5.1 Introduction
Faced with the inability to isolate high-affinity Ga-DOTA-biotin binders that
could be used as the hapten-specific part of a bispecific targeting agent for PRIT, we
considered alternative approaches. We proposed to take advantage of an existing
extremely high-affinity scFv (4M5.3) against fluorescein [1, 2] to construct a bispecific
target agent that could be used to deliver any radioisotope desired in a PRIT setting. In
this approach, the hapten-specific part of the bispecific target agent binds fluorescein
with very high affinity, and the radioisotope of choice is conjugated to the fluorescein
molecule.
While this approach was conceived as an alternative to a hapten-binding part of
the targeting agent that binds directly to the metal chelate, it actually has several
advantages over the direct-binding approach. First, the method is generic with respect to
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metal chelate conjugated and radioisotope loaded. It appears from other researchers'
work [3, 4] and our own results (see Chapter 4) that the binding of anti-metal-chelate
antibodies is dependent on the metal loaded into the chelate. While this specificity is
impressive and scientifically interesting, it is not necessarily advantageous - it potentially
requires that a new antibody be isolated, engineered, charaterized and approved for each
different radioisotope proposed for use in PRIT or pretargeted imaging. By using a
fluorescein-binding antibody as the hapten-binding half of the targeting agent, a single
targeting agent can be used to deliver many different radioisotopes, and conceivably
other types of cytotoxic payloads.
The second advantage of using fluorescein binding to link bispecific and hapten is
that fluoresceiLn-tetramethylrhodamine (TMR) bifluorophores have been developed that
have altered fluorescent properties in the presence of fluorescein-binding proteins [5].
Fluorescein and TMR are structurally similar, and when conjugated to each other a ring-
stacking interaction leads to a substantial decrease in the fluorescence of both dyes.
However, in the presence of fluorescein-binding proteins this interaction is disrupted, and
TMR recovers its normal fluorescent properties. As a result, these bifluorophores can be
used as molecular reporters for the presence of fluorescein-binding proteins. We
anticipate that: these molecules may be extremely useful in in vitro cell spheroid imaging
studies, since they can be used to pinpoint the location of not just hapten, but of hapten-
bispecific complexes.
After deciding to pursue an anti-CEA, anti-fluorescein bispecific targeting agent,
it was necessary to decide on a molecular format for protein. A wide variety of antibody-
fragment based molecular formats are available for the synthesis of a bispecific agent,
including conjugated scFvs [6], non-covalent diabodies [7, 8], single-chain diabodies [8],
and more exotic constructions such as triabodies and larger fusion proteins [9]. A
targeting agent with molecule weight just higher that the 50 kD molecular weight cutoff
was considered ideal, since such a targeting agent would avoid very rapid clearance from
the plasma, but would not be hindered in tumor penetration by the low diffusivity of a
higher molecular weight protein such as a full IgG. This molecular weight requirement
ruled out larger fusion proteins and non-covalent combinations such as triabodies and
tetrabodies. Single-chain diabodies were selected as an ideal diabody format, as post-
expression conjugation of scFvs and covalently-formed diabodies between co-secreted
molecules both suffer from heterogeneity in protein formulations, which is a problem
both in pre-clinical development and a potential problem further down the drug
development pipeline. Single-chain diabodies had previously only been secreted in E.
coli, but the ability of S. cerevisiae to secrete complex, multi-domain heterologous
proteins [10, 11] suggested that it would be possible to secrete single-chain diabodies
from yeast.
5.2 Methods
5.2.1 Single-chain bispecific diabody gene synthesis
Single-chain diabodies are composed of four variable domains in the following
order: V,'-L10-VL2-LL-VH2-L10-VL1', where VH1 and VL1 are the variable domains of a
particular scFv, VH2 and VL2 are the variable domains of another, and L10 and LL are
linker regions with the amino acid sequences AKTTPKLGGL and
RADAAAAGGGGSGGGGSGGGG, respectively. Initially, we had intended for the
diabody to bind directly to the metal chelate hapten Ga-DOTA-biotin and the cancer-
specific protein antigen CEA. The diabody was therefore designed with VH1' and VL1
regions taken from the best available anti-Ga-DOTA-biotin clone at the time, clone 17.
V, 2 and VL2 were taken from sm3E, a high-affinity scFv previously developed against
CEA [12].
The variable domains from clone 17 and sm3E were amplified via PCR, and then
assembled in two steps. First, overlap extension PCR was used to construct VH1-L10-VL2-
LL and LL-V 2'-L10-VL1' fragments [13], and then those two fragments were combined
into the desired gene by utilizing homologous recombination in yeast [14]. The initial
annotated sequence of the single-chain diabody gene is shown below as Figure 5.1.
Nhe I 17 VH
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GCTAGCCAGGTGCAGCTGCAGGAGTCCGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACGTGCACTGTC
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TTGACTATTAGCTCAGTGCAGCCAGAGGATGCTGCAACCTACTATTGCCAGCAAAGGTCCTCATATCCACTGACTTTC
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GGGGGTGGAACGAAGTTGGAAATCAAGGCTGCAGCCGGATCGACGTCAAGAGCTGATGCTGCTGCTGCTGGTGGTGGT
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GGTTCTGGTGGTGGTGGTTC TGGTGGTGGTGGTTCAAGTTAAACTGGAACAGTCCGGTGCTGAAGTTGTC
K P GAS VKL SC K A S G F N I K D S Y M H W L R
AAACCAGGTGCTTCCGTGAAGTTGTCCTGTAAAGCCTCTGGTTTTAACATCAAGGATTCGTATATGCATTGGTTGAGA
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CAAGGGCCAGGACAAAGATTGGAATGGATTGGCTGGATTGATCCAGAGAATGGTGATACCGAGTACGCTCCTAAATTT
Q G K AT FT T D T SAN T AY L G L SS L R P E D
CAGGGAAAGGCTACTTTTACTACCGACACTTCCGCTAATACCGCATACTTGGGCTTATCTTCCTTGAGACCAGAGGAC
T AV Y Y C NE G T PT G P Y Y F DY WGQ G T LV
ACTGCCGTATACTACTGCAACGAAGGGACACCAACTGGTCCTTACTATTTCGACTACTGGGGACAAGGTACCTTAGTT
Nar I L10 Sph I 17 VL
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ACTGTCTCTAGCGGCGCCTCTGCTAAAACTACTCCAAAATTAGGTGGCATGCTAGAAATTGTGTTGACACAGTCTCCA
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GCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAACTTAGCC
W Y Q H K P G Q A P R L L I S G S S S R A T G I P D
TGGTACCAGCACAAACCTGGCCAGGCTCCCAGGC TCATCTCTGGTTCATCCAGTAGGGCCACTGGCATCCCAGAC
R F S G S G S G T D F T L T I S R L E P E D F A V Y
AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTAT
Y C Q Q Y D TSP IT F G PG T K V DI KS GIL E
TACTGTCAGCAGTATGATACGTCACCGATCACTTTCGGCCCTGGGACCAAAGTGGATATCAAATCCGGAATTCTAGAA
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Figure 5.1 Annotated DNA and amino acid sequence of 3A-1C, a single-
chain diabody composed of the variable regions of the anti-Ga-DOTA-biotin
scFv 17 and the anti-CEA scFv CEA.
Because of difficulties in isolating high-affinity Ga-DOTA-biotin binders and the
advantages of an alternative approach, we decided to design a bispecific molecule to bind
to a fluorescein-based hapten, rather than directly to a radiometal chelate. This approach
has the advantage of being generic - the same bispecific molecule can be used to deliver
any radioisotope in almost any metal chelate without modification.
To implement this approach, we amplified the VH and VL regions of the anti-
fluorescein scFv 4M5.3 [1] from an existing plasmid in the lab, and subcloned these
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regions into the diabody construct shown in Fig. 5.1, in place of the anti-Ga-DOTA-
biotin scFv 17. The resulting annotated DNA and amino acid sequence (referred to as
4sdb-1) is shown below as Fig. 5.2.
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Figure 5.2. The annotated DNA and protein sequence of 4sdb-1, a single-
chain bispecific diabody composed of the variable regions of the anti-
fluorescein scFv 4M5.3 and the anti-CEA scFv sm3E.
As noted in Figs. 5.1 and 5.2, each variable region in the diabody is flanked with
restriction sites, so that subcloning new variable regions of interest into the diabody is
straightforward.
5.2.2 Single-chain bispecific expression in S. cerivisiae and purification
The anti-sm3E, anti-fluorescein single-chain bispecific diabody referred to as
4sdb-1 was secreted from S. cerivisiae (strain YVH10 [15]). After sequencing to confirm
the correct DNA sequence, the plasmid was subcloned into a secretion vector containing
the optimized alpha prepreo leader sequence S4 [16]. In this vector, 4sdb-1 is fused to a
N-terminal FLAG epitope tag and a C-terminal his6 epitope tag, to provide different
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options for purification and characterization. This plasmid was transformed into YVH10O
cells, and grown at 300C to an optical density/ml (OD/ml; absorbance at 600 nm per mL
culture) of 10 in a 5 mL culture of SD-CAA supplemented with uracil (0.04 mg/mL).
The fully-grown culture (50 OD, or approximately 5 x 108 cells total) was innoculated
into IL of SD-CAA with uracil and a 1:100 dilution of penicillin-streptomycin (stock
concentration 10,000 units/mL penicillin, 10,000 [xg/mL streptomycin). The liter culture
was grown at 300 C until a cell density of 5 OD/ml was obtained. The cells were
harvested via centrifugation (5 minutes at 3000g in bottles), the supernatant was
removed, and the cells were resuspended in 1 L of YPG with penicillin-streptomycin.
Induction took place at 200 C in unbaffled glass flasks with constant shaking. After two
days of induction, the supernatant was collected via centrifugation as above and filtered
using a 0.2 Rm bottle-top filter to remove any remaining cells from the supernatant.
The supernatant was concentrated from a volume of 1 L to 50 mL using an
Amicon stirred-cell concentrator (Millipore) at room temperature. 250 mL of TBS (pH
7.5) was added to the concentrated supernatant, and the pH of the buffered supernatant
was adjusted to 7.5 with the addition of 12M NaOH. The buffered supernatant was
concentrated from a volume of 300 mL to 50 mL using a stirred cell concentrator at room
temperature. The concentrated, buffered supernatant was sterilized by filtration, and
stored in a 50 mL conical tube until purification.
The concentrated, buffered supernatant was added to 1 mL of anti-FLAG M2
agarose resin (Sigma) that had been pre-equilibrated with TBS, pH 7.5. The supernatant
and resin were allowed to equilibrate for 1 hour at room temperature, after which the
resin was washed once with 10 mL TBS. The resin was applied to a chromatography
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column, and the diabody was eluted with the addition of 5 1 mL fractions of 0.1M
glycine HCL, pH 3.5.
The presence of diabody in the eluted fractions was determined by SDS-PAGE
with a NuPAGE 4-12% Bis-Tris minigel (Invitrogen) followed by Coomassie staining.
Elution fractions that appeared to contain the diabody were collected, concentrated using
a Centricon device (Millipore) and purified using size exclusion chromatography on a
Superdex 75 column (GE Healthcare) using TBS as a running buffer. The final
concentration of purified, full-length diabody was estimated by measuring the absorbance
at 280 nm of the fractions eluted from the size exclusion column.
5.2.3 Characterization of anti-CEA, anti-fluorescein single-chain bispecific diabody
on the surface of CEA-expressing mammalian cells
Purified anti-CEA, anti-fluorescein single-chain bispecific diabody was
concentrated from fractions eluted during size exclusion chromatography to
approximately 150 [tL. A fraction of the purified diabody was labeled with the Alexa-
488 dye using the Alexa-488 Microscale Labeling Kit (Invitrogen). Separation of the
dye-labeled protein from the unreacted fluorophore was verified using thin-layer
chromatography.
SW1222 cells conservatively estimated to be expressing CEA at approximately
500,000 copies / cell [17, 18] were grown in advanced MEM cell culture media
supplemented with fetal bovine serum and L-glutamine in stationary cell culture at 370C
in 5% CO2/95% air. Cells were lifted from cell tissue culture plates using trypsin and
Versene, collected and counted with a hemacytometer. Between 6 and 30 million cells
were collected per lifting from 75 cm 2 tissue culture plates.
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Cells were labeled with unlabeled bispecific that had been purified using the anti-
FLAG resin, but had not yet been purified via size exclusion chromatography. Based on
subsequent quantification of the concentration of full-length protein, the concentration of
full-length bispecific used to label cells was 40 nM. Cells labeled with bispecific were
incubated with anti-FLAG and anti-his6 antibodies to demonstrate the presence of the
bispecific on the surface of the cells. Cells were also labled with fluorescein-biotin,
followed by streptavidin-PE, to demonstrate the ability of the cell-bound bispecific to
bind a fluorescein-conjugated hapten. All binding was measured using flow cytometry
on a Coulter Epics® XL flow cytometer. In all cases, negative controls were performed in
which the bispecific was not included in the cell labeling mixture, to ensure that the
binding of secondary reagents was not nonspecific.
After demonstrating the presence of bispecific on the surface of CEA-expressing
SW1222 cells, and demonstrating the ability of cell-bound bispecific to bind fluorescein,
the affinity of the bispecific diabody for cell-expressed CEA was measured. Alexa-488-
labeled diabody was incubated with SW1222 cells (4 x 105 per labeling) at concentrations
varying from 60 pM to 30 nM. In all labeling experiments, the diabody was in excess
compared to the number of CEA molecules, ensuring that depletion of soluble diabody
would not affect the equilibrium measurement. Cells and diabody were incubated for 4
hours at 370C, after which the mean fluorescence of cells was measured by flow
cytometry. As a control, three tubes were labeled exactly the same as the tubes with the
highest concentrations of bispecific (7.5 nM, 15 nM and 30 nM), except that the cells
were pre-blocked for 30 minutes at 37°C with 10 pL of 10 LM disulfide-stabilized sm3E
dimer. Since the high affinity sm3E dimer would bind all of the CEA on the cells, this
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allowed the measurement of background concentration-dependent binding of Alexa-488-
labeled diabody to the SW1222 cells. The Kd of 488-labeled bispecific diabody was
determined by a non-linear least-squares fit to the data.
5.3 Results
5.3.1 Single-chain bispecific expression in S. cerivisiae and purification
Single-chain bispecific diabody 4sdb-1 was secreted in S. cerevisiae and purified
using an anti-FLAG M2 agarose resin. The diabody was eluted in 5 1 mL fractions of
0.1M glycine HCL, pH 3.5. Each fraction was collected in a 1.5 mL Eppendorf
microfuge tube containing 25 [tL of 1M Tris-Hcl, pH 7.0. 12 [LL of each collected
fraction was analyzed using reducing SDS-PAGE and stained using SimplyBlueTM
Safestain (Invitrogen), as shown in Fig. 5.3 below.
Figure 5.3. Coomassie stain of SDS-PAGE gel loaded with fractions eluted
from anti-FLAG purification resin. Molecular weight ladder is Full Range
Rainbow Ladder (GE Healthcare).
As shown in Fig. 5.3, the full length protein (expected size ~ 55 kDa) was present
in eluted fractions 1, 2 and 3. In addition, a smaller protein fragment approximately 30
kDa in size was also present. Fractions 1, 2 and 3 were collected, concentrated and
further purified via FPLC on a Superdex 75 size exclusion column. The absorbance at
280 nm of each fraction eluted from the Superdex 75 size exclusion column was
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measured, and the resulting chromatagraph is shown in Fig. 5.4, along with BSA (66
kDa) and lysozyme (14 kDa) standards.
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Figure 5.4. Elution of FLAG-purified bispecific diabody from a Superdex
75 size exclusion chromatography column. Solid line, diabody; dashed line,
BSA and lysozyme standards.
As shown in Fig. 5.4, the major peak in the size exclusion chromatography
fractions occurs just after the standards peak correpsonding to 66 kDa BSA, where a
protein approximately 55 kDa in size would be expected to elute. Smaller peaks before
and after the major peak are likely composed of noncovalent dimers and truncated
versions of the full-length protein. The fractions corresponding to the major peak were
collected and concentrated. Based on absorbance measurements at 280 nm,
approximately 80 [g of purified, full-length diabody was present. These fractions were
concentrated to a final volume of 150 ptL, and the buffer was changed from TBS to PBS
via dialysis using an ElutaTube (Invitrogen).
5.3.2 Characterization of anti-CEA, anti-fluorescein single-chain bispecific diabody
on the surface of CEA-expressing mammalian cells
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A fraction of the purified diabody was labeled with the Alexa-488 dye using the
Alexa-488 Microscale Labeling Kit (Invitrogen). Separation of the dye-labeled protein
from the unreacted fluorophore was verified using thin-layer chromatography, as shown
in Fig. 5.5.
Figure 5.5. Thin layer chromatography of Alexa-488 labeled bispecific
diabody. On the left, a control sample containing both labeled protein
(black dot) and unreacted fluorophore (two bands). On the right, sample of
Alexa-488 labeled bispecific diabody contains no unreacted fluorophore.
SW1222 cells expressing CEA at approximately 500,000 copies / cell were
labeled with unlabeled bispecific that had been purified using the anti-FLAG resin, but
had not yet been purified via size exclusion chromatography. Based on subsequent
quantification of the concentration of full-length protein, the concentration of full-length
bispecific used to label cells was 40 nM. Cells labeled with bispecific were incubated
with anti-FLAG and anti-his6 antibodies to demonstrate the presence of the bispecific on
the surface of the cells. As shown in Fig. 5.6 and 5.7, the binding of anti-FLAG and anti-
his6 antibodies to SW1222 cells was dependent on the presence of bispecific, indicating
that epitope-tagged bispecific was present on the surface of the cells. The binding of
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anti-his antibody to bispecific localized to the surface of SW1222 cells also indicates that
the bispecific diabody is full-length, as the his tag is a C-terminal tag in this construct.
U anti-FLAG-biotin + s-PE
U bs + anti-FLAG-biotin + s-PE
iI
100 101 102 103 104
FL2 LOG: FL2 LOG
Figure 5.6. The binding of anti-FLAG antibody to SW1222 cells. SW1222
cells were incubated with 1 [tL of 0.21 mg/mL bispecific diabody (bs), 1 tiL
of 1.2 mg/mL biotinylated anti-FLAG M2 antibody (anti-FLAG-biotin), and
1 pL of 1 mg/mL streptavidin-phycoerithryn (s-PE) in 100 ItL of PBS/BSA
on ice. Bispecific was incubated with the cells for 60 minutes, while anti-
FLAG antibody and streptavidin-PE were incubated with cells for 15
minutes. Cell fluorescence was measured via flow cytometry; PE
fluorescence was measured with the FL2 channel. The cells were washed
with 0.5 ml cold PBS/BSA before each label was added. Histogram is shown
on the left, while the average fluorescence of each cell labeling is shown on
the right.
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Figure 5.7. The binding of anti-his antibody to SW1222 cells. SW1222 cells
were incubated with 1 1%L of 0.21 mg/mL bispecific diabody (bs), 1 pL of 0.5
mg/mL tetra-his anti-his6 antibody (tetra-his), and 1 R&L of 1 mg/mL Alexa-
488 labled goat anti-mouse antibody (gam-488) in 100 pL of PBS/BSA on ice.
Bispecific was incubated with the cells for 60 minutes, while anti-his
antibody and goat anti-mouse antibody were incubated with cells for 15
minutes. Cell fluorescence was measured via flow cytometry; PE
fluorescence was measured with the FL1 channel. The cells were washed
with 0.5 ml cold PBS/BSA after each label was added. Histogram is shown
on the left, while the average fluorescence of each cell labeling is shown on
the right.
Cells labled with bispecific diabody were also labeled with fluorescein-biotin,
followed by streptavidin-PE, to demonstrate the ability of the cell-bound bispecific to
bind a fluorescein-conjugated hapten. As shown in Figure 5.8, the binding of
fluorescein-biotin to SW1222 cells is dependent on the presence of bispecific, indicating
that the fluorescein biotin is being bound by the bispecific molecule on the surface of the
cell.
110
100
80
1 00
101 102 103
FL2 LOG: FL2 LOG
U fl-biotin + s-PE
JU bs + fl-biotin + s-PE
6e0 t
612:if
104
Figure 5.8. The binding of fluorescein-biotin to SW1222 cells. SW1222 cells
were incubated with 1 pL of 0.21 mg/mL bispecific diabody (bs), 1 2pL of 6
mM fluorescein-biotin (fl-biotin), and 1 .pL of 1 mg/mL streptavidin-PE
(strep-PE) in 100 ptL of PBS/BSA on ice. Bispecific was incubated with the
cells for 60 minutes, while fluorescein-biotin and streptavidin-PE were
incubated with cells for 15 minutes. Cell fluorescence was measured via flow
cytometry; PE fluorescence was measured with the FL2 channel. The cells
were washed with 0.5 ml cold PBS/IBSA before each label was added.
Histogram is shown on the left, while the average fluorescence of each cell
labeling is shown on the right.
After demonstrating the presence of bispecific on the surface of CEA-expressing
SW1222 cells, and demonstrating the ability of cell-bound bispecific to bind fluorescein,
the affinity of the bispecific diabody for cell-expressed CEA was measured. Alexa-488-
labeled diabody was incubated with SW1222 cells (4 x 105 per labeling) at concentrations
varying from 60 pM to 30 nM. Cells and diabody were incubated for 4 hours at 370 C,
after which the mean fluorescence of cells was measured by flow cytometry. Control
cells pre-blocked with high-affinity disulfide-stabilized sm3E dimer indicated no
concentration-dependent nonspecific binding of diabody at the concentrations measured.
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Figure 5.8. Binding of Alexa-488 bispecific diabody to CEA-expressing
SW1222 cells. Cells were incubated with varying concentrations of
fluorescently-labeled diabody for 4 hours, and then fluorescence was
measured via flow cytometry. Background fluorescence (as measured by
three tubes of cells pre-blocked with disulfide-stabilized sm3E dimer) was
concentration independent at the concentrations tested, and was subtracted
from each data point. Squares are data points, and the line is a non-linear
least squares fit for a measured Kd of 4.3 * 2.5 nM.
As shown in Fig. 5.8, the Kd of bispecific diabody for CEA expressed on the
surface of SW1222 cells at 370C is 4.3 ± 2.5 nM. This is significantly lower than the
affinity of sm3E, the scFv which the CEA-binding part of the bispecific is based on, for
CEA, which has been measured to be 30 pM at 250 C [12]. The decrease in affinity is
likely due to altered orientation of the variable domains as a result of the scFv being
reformated into a single-chain bispecific diabody.
5.4 Conclusions & Discussion
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A novel bispecific targeting agent for PRIT has been designed, produced, purified
and characterized. Rather than binding directly to a radioisotope-carrying metal chelate,
this single-chain bispecific diabody binds to fluorescein, which can be conjugated to
almost any metal chelate/radioisotope pairing of therapeutic interest. As a result, this
targeting agent can be used to deliver a wide variety of radioisotopes to CEA-expressing
cancer cells. In addition, the targeting agent can be easily modified to target any
particular cancer-specific marker molecule that is desired.
The diabody is secreted from yeast as a full-length, 55 kDa protein that can be
cleanly purified by anti-epitope-tag affinity chromatography and size exlusion
chromatography. A truncated version of the approximately 30 kDA is size is also present
in the unpurified supernatant. This variant may be a mixture of proteolysis products
resulting from linkage cleavage, or it may be a truncated version of the diabody that
arises in the yeast secretory system due to unknown causes. The total yield of full-length
protein was low (80 [tg/L), possibly due to the difficulty of secreting a four-variable-
domain protein fusion, but subsequent optimization of the secretion conditions should
result in improved yields. This was the first known single-chain bispecific diabody
expressed in S. cervisiae.
The bispecific diabody binds CEA expressed on the surface of SW1222 cells with
a Kd of 4.3 - 2.5 nM. This affinity is intermediate between anti-CEA scFvs sm3E and
shMFE, which have Kds of 30 pM and 8 nM, respectively. The bispecific diabody
contains the variable regions of sm3E, and the lower affinity is likely a result of an
altered orientation of the variable domains as a result of being expressed in a single-chain
diabody. Both the physical constraints upon the protein and the linker regions used to
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connect the variable domains are different in the diabody format than in the scFv format,
so it is not suprising to see that the affinity has decreased. In addition, it has also been
demonstrated that the diabody binds fluorescein-biotin, a model fluorescein-based hapten
molecule, while binding CEA on the surface of SW1222 cells.
This anti-CEA, anti-fluorescein single-chain bispecific diabody can be used in the
future preclinical PRIT studies. Future work should include experiments to follow the
diffusion, binding and catabolism of diabody in cancer cell-spheroids. Additionally, it
should be possible to use fluorescein-tetramethylrhodamine bifluorophores as molecular
reporters of diabody-fluorescein binding, allowing for a far clear picture of PRIT on a
cellular level than has been achievable to date. It may also be desirable to further
engineer this bispecific diabody, in order to either increase its affinity for CEA and
fluorescein, or to modulate those interactions. For example, it might be desirable to
engineer the anti-fluorescein portion of diabody so that it binds fluorescein with high
affinity at pH 7, but at a much lower affinity at pH 5. This modified diabody, if
internalized upon binding at the cell surface and recycled back to the cell surface, could
then potentially be used to deliver multiple payloads of radioactive hapten. In summary,
this anti-CEA, anti-fluorescein single-chain bispecific diabody provides a tool for
improved understanding of PRIT at the cellular and micrometastasic levels, and provides
a framework for designing future antibody-based targeting agents for PRIT treatments.
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2001 Honorable Mention, NSF Graduate Research Fellowship Program
2001 American Chemical Society, Philadelphia Section, Annual Award,
Philadelphia, PA
2000 American Institute of Chemical Engineers, Delaware Valley Section,
Outstanding Chemical Engineering Student at the University of
Pennsylvania, Philadelphia, PA
SKILLS
MOLECULAR
PCR (standard, mutagenic, overlap-extension, touchdown, phage), DNA
library construction (random mutagenesis, chain shuffling, homologous
recombination in S. cerevisiae), site-directed mutagenesis, subcloning
(restriction digestion, ligation), DNA electrophoresis, DNA sequencing,
DNA fingerprinting, protein purification (FPLC, ion-exchange, gel
filtration, hydrophobicity and affinity chromatography), SDS-PAGE,
western blotting, ELISAs, biotinylation.
CELLULAR
Directed evolution of peptides and proteins via yeast surface display and
phage display, magnetic cell sorting (MACS), flow cytometry, fluorescent-
activated cell sorting (FACS), phage panning, phage-ELISAs, protein
expression in S. cerevisiae, microscopy (light, fluorescent, and confocal).
LEADERSHIP EXPERIENCE
2006 Served as part of a team of teaching assistants administering
a chemical & biological engineering projects laboratory.
Interacted with professors and students to plan meetings,
prepare materials, and resolve interpersonal conflicts.
2003-2005 Supervised three undergraduate research assistants who
assisted with laboratory work and computer programming.
2003 Program Director at WMBR-88.1 FM (MIT's college radio
station) for three seasons. Responsible for all broadcast
content; appointed programming boards, and with those
boards determined the program schedule for each season.
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OTHER INTERESTS
The repair and maintenance of vintage and modern motorscooters, amateur
audio electronics, homebrewing beer, and sailing.
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